Multiplex detection of respiratory viruses

Specific primers and probes for SARS-CoV-2, Influenza A, B, and RSV enable rapid, sensitive, and specific multiplex detection, addressing the limitations of current diagnostic methods by enabling same-visit diagnosis and treatment.

WO2026238935A1PCT designated stage Publication Date: 2026-11-19DIAGNOSTICS FOR THE REAL WORLD LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/064163
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-27
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current diagnostic methods for respiratory viruses like SARS-CoV-2, Influenza A, Influenza B, and RSV suffer from limited sensitivity, longer turnaround times, and the need for centralized facilities, leading to delayed diagnosis and treatment, especially in developing countries, with a lack of rapid, sensitive, and specific point-of-care (POC) testing solutions.

Method used

Development of primers and probes specific to the ORF1ab and ORF8 genes of SARS-CoV-2, Matrix Protein (MP) and Polymerase Protein 2 (PB2) genes of Influenza A, Non-structural Protein (NS) and Polymerase Protein (PB2) genes of Influenza B, and Phosphoprotein (P) genes of RSV, enabling amplification and detection using PCR, with detector probes for accurate identification.

Benefits of technology

Facilitates rapid, sensitive, and specific detection of multiple respiratory viruses simultaneously, allowing same-visit diagnosis and treatment, reducing patient loss to follow-up and curbing transmission.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026064163_19112026_PF_FP_ABST
    Figure EP2026064163_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Methods for detecting nucleic acid of viruses responsible for respiratory diseases, including detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A, Influenza B and Respiratory syncytial virus (RSV) are described. The methods comprise amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of a sample, by an amplification reaction using a forward and a reverse nucleic acid amplification primer, wherein each nucleic acid amplification primer hybridises specifically to SARS-CoV-2 nucleic acid, and / or Influenza A nucleic acid, and / or Influenza B nucleic acid, and / or RSV nucleic acid, or the complement thereof. The methods are particularly useful for point-of-care (POC) testing. Kits, primers, probes, sets of primers, sets of oligonucleotides, and oligonucleotides, and their use in the methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] P107173W001

[0002] 1

[0003] MULTIPLEX DETECTION OF RESPIRATORY VIRUSES

[0004] FIELD OF THE INVENTION

[0005] This invention relates to methods for detecting nucleic acid of viruses responsible for respiratory diseases, including detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A, Influenza B and Respiratory syncytial virus (RSV) particularly for point-of-care (POC) testing, and to kits, primers, probes, sets of primers, sets of oligonucleotides, and oligonucleotides, and their use in the methods.

[0006] BACKGROUND

[0007] The 2019 coronavirus pandemic is a global outbreak of COVID-19 caused by SARS-CoV-2. First identified in Wuhan, Hubei, China, in December 2019, the outbreak was recognised as a pandemic by the World Health Organization (WHO) on 11 March 2020. As of 13 April 2024, more than 7,000,000 deaths have been reported globally with individuals infected with SARS-CoV-2 (URL: https: / / www.worldometers.info / coronavirus / coronavirus-death-toll / #google_vignette).

[0008] Coronaviruses (CoVs) belong to the Coronaviridae family of viruses, all of which are enveloped. CoVs contain a single-stranded positive-sense RNA genome, with a length of between 25 and 31 kilobases (Siddell S.G. 1995, The Coronaviridae), the largest genome so far found in RNA viruses. SARS-CoV-2 RNA sequence is approximately 30,000 bases in length (see the SARS-CoV genome organisation shown in Figure 1). The Coronaviridae family are subtyped into four genera: a, p, y, and 5 coronaviruses, based on phylogenetic clustering, with each genus subdivided again into clusters depending on the strain of the virus. For example, within the genus -CoV (Group 2 CoV), four lineages (a, b, c, and d) are commonly recognized:

[0009] • Lineage A (subgenus Embecovirus) includes HCoV-OC43 and HCoV-HKU1 (various species)

[0010] • Lineage B (subgenus Sarbecovirus) includes SARSr-CoV (which includes all its strains such as SARS-CoV, SARS-CoV-2, and Bat SL-CoV-WIV1)

[0011] • Lineage C (subgenus Merbecovirus) includes Tylonycteris bat coronavirus HKU4 (BtCoV-HKU4), Pipistrellus bat coronavirus HKU5 (BtCoV-HKU5), and MERS-CoV (various species)

[0012] • Lineage D (subgenus Nobecovirus) includes Rousettus bat coronavirus HKU9 (BtCoV-HKU9)P107173W001

[0013] 2

[0014] CoV virions are spherical with characteristic club-shape spike projections emanating from the surface of the virion. The virions contain four main structural proteins: spike (S); membrane (M); envelope (E); and nucleocapsid (N) proteins, all of which are encoded by the viral genome. Some subsets of p-CoVs also comprise a fifth structural protein, hemagglutinin-esterase (HE), which enhances S protein-mediated cell entry and viral spread through the mucosa via its acetyl-esterase activity. Homo-trimers of the S glycoprotein make up the distinctive spike structure on the surface of the virus. These trimers are a class I fusion protein, mediating virus attachment to the host receptor by interaction of the S protein and its receptor. In most CoVs, S is cleaved by host cell protease into two separate polypeptides - S1 and S2. S1 contains the receptor-binding domain (RBD) of the S protein (the exact positioning of the RBD varies depending on the viral strain), while S2 forms the stem of the spike molecule. The N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope.

[0015] Most common symptoms include fever, cough, tiredness and / or loss of taste or smell which typically occur five to six days after infection but can take up to 14 days. Most people that become infected will develop mild to moderate illness and recover without hospitalisation. The elderly and those with underlying health conditions are at greater risk from developing serious symptoms.

[0016] The genome of SARS-CoV-2 is comprised of a single-stranded positive-sense RNA and is approximately 29.9 kb in size. The genetic makeup of SARS-CoV-2 consists of 13-15 open reading frames (12 of which are functional), containing around 30,000 nucleotides. The genome has a GC content of 38% and includes 11 protein-coding genes, with 12 expressed proteins. This genetic complexity underpins the virus’s ability to infect hosts and adapt to new environments.

[0017] Although no longer in a global health emergency, SARS-CoV-2 continues to infect individuals globally. The virus also continues to accrue mutations, most significantly in the spike protein, generating variants of concern (VOCs) which have implications for increased transmission and escape from natural and vaccine immunity. The continued emergence of these VOCs during the on-going COVID-19 pandemic highlights the need for rapid diagnosis of SARS-CoV-2 infection to curtail infections by reducing transmission of the virus and thereby hamper the rate of mutation accumulation.

[0018] Being able to test, identify and treat individuals infected with SARS-CoV-2 without delay is critical. Nucleic acid testing (NAT) is state of the art for diagnosis of infectious disease and usually requires highly trained staff and specialized facilities available only in sophisticated, centralized laboratories. Some NATs also require samples to be sent frozen or refrigerated;P107173W001

[0019] 3

[0020] with turnaround times of 2-3 days for results leading to ‘loss-to-follow-up,’ a common problem in developing countries. Despite draconian efforts by central and local authorities, many countries experienced long delays in testing results during the COVID-19 pandemic, especially in hospitals without NAT testing capacity. This limitation is also seen in other settings such as cruise ships. Amplicon contamination was also a major issue in some countries, causing false positives, a common problem for NATs.

[0021] NATs have since developed which provide point-of-care (POC) diagnostic tests for COVID-19 for use in the community. Such testing is fully automated, negating the need for highly trained staff and specialised facilities. Minimal handling by the testing staff also minimises the risk of cross contamination and false positives.

[0022] However, there is still a need for rapid diagnosis of SARS-CoV-2 which is highly sensitive and specific for SARS-CoV-2. Similarly, there is a need for rapid diagnosis of Influenza A, Influenza B and Respiratory syncytial virus as well as for multiplex assays for rapid diagnosis of multiple pathogens simultaneously which addresses the frequent occurrence of coinfections with these respiratory viruses.

[0023] Influenza A is an acute respiratory viral infection (ARI), a respiratory illness caused by infection with the influenza A virus H1N1, characterised by the sudden onset of high fever, chills, cough, runny nose, sore throat, headache, and muscle aches. Most influenza A symptoms are mild and typically resolve on their own within 5 to 7 days. Nevertheless, individuals who develop severe symptoms may experience a persistent high temperature of 38°C or higher lasting 7 to 10 days or more, along with serious complications such as severe pneumonia, shortness of breath, rapid breathing, respiratory failure, seizures, and, in rare cases, death.

[0024] The virus spreads from person to person through direct contact with bodily secretions such as nasal discharge, saliva, phlegm, or respiratory droplets produced by coughing and sneezing. Indirect transmission can also occur via virus-contaminated objects like doorknobs, handrails, or personal items, especially when contaminated hands come into contact with the nose or mouth, allowing the virus to enter the upper respiratory tract, including the nasal cavity, sinuses, and throat. Following this, the virus rapidly proliferates and replicates before descending into the lower respiratory tract, affecting the larynx, bronchi, and lungs. Both symptomatic and asymptomatic individuals can transmit the virus to others, usually within 1 to 3 days of infection.

[0025] Influenza A has a segmented RNA genome with varying GC content across its eight segments, generally around 41-47%. The Influenza A genome is approximately 13.5 kb.P107173W001

[0026] 4

[0027] Influenza B is caused by the influenza B virus, a member of the Orthomyxoviridae family. The influenza B virus spreads easily from person to person through respiratory droplets released when an infected individual coughs or sneezes, making close contact a key factor in transmission. It can also be transmitted by touching contaminated surfaces and then touching one's face without washing hands.

[0028] Like influenza A, the symptoms of influenza B typically emerge one to four days after exposure and can range from mild to severe. Common signs include sudden onset of fever or chills, body aches and muscle pain, headache, fatigue, congestion, runny or stuffy nose, sore throat, and, in some cases, nausea and vomiting. Most people recover within a week as symptoms gradually subside.

[0029] Influenza B almost exclusively infects humans and is less common than influenza A. Flu type B also mutates about two to three times more slowly than influenza A. Because humans are the natural host of influenza B, pandemics generally do not occur with influenza B viruses.

[0030] Influenza B virus has a segmented RNA genome with varying GC content across its 8 segments, generally falling in the 40-47% range. The influenza B virus genome is 14,548 nucleotides long.

[0031] Respiratory syncytial virus (RSV) is a respiratory pathogen, particularly affecting infants, young children, and the elderly. RSV is an enveloped, negative-sense, single-stranded RNA genome of 15 kb that encodes 11 viral proteins. There are two major antigenic subtypes of RSV: type A and type B.

[0032] RSV typically causes mild, cold-like symptoms, but it can lead to more severe respiratory illness in vulnerable populations. The virus is primarily spread through droplets produced when an infected person coughs or sneezes, and it can survive on surfaces or objects for several hours, facilitating indirect transmission.

[0033] Given the ability of SARS-CoV-2, Influenza A, Influenza B, and RSV to present with both symptomatic and asymptomatic infections, prioritising early detection is essential for effective clinical management and public health intervention. Historically, conventional diagnostic approaches such as viral culture or centralised PCR testing often suffered from limited sensitivity and longer turnaround times, which could delay diagnosis and treatment.

[0034] The advent of rapid nucleic acid amplification tests (NAATs) has transformed respiratory virus detection, providing enhanced sensitivity and specificity and enabling reliable results directly from swab samples. Importantly, the development of multiplex assays capable ofP107173W001

[0035] 5

[0036] detecting multiple pathogens simultaneously addresses the frequent occurrence of coinfections. This approach streamlines the diagnostic workflow, minimising the need for separate tests and accelerating result delivery.

[0037] Such rapid, point-of-care solutions facilitate same-visit diagnosis and treatment, reducing the risk of patient loss to follow-up and allowing quicker initiation of appropriate therapy. Ultimately, accurate and swift detection methods not only improve individual patient outcomes but also play a crucial role in curbing transmission and preventing the serious complications associated with respiratory infections.

[0038] DESCRIPTION

[0039] The invention disclosed herein is as set out in the appended claims.

[0040] Detection of SARS-CoV-2

[0041] Primers and probes specific to SARS-CoV-2, which hybridise to the ORFIab and ORF8 genes have been designed.

[0042] According to the invention there is provided a method for determining whether a sample includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:

[0043] i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAGGACAATCAGACAACTACTATTC (SEQ ID NO:1), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / or

[0044] ii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4); or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises aP107173W001

[0045] 6

[0046] nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0047] Optionally, the method further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to SARS-CoV-2 nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

[0048] Optionally, a product of the amplification reaction using the primer pairing (i) for amplifying SARS-CoV-2 nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof;

[0049] a product of the amplification reaction using the primer pairing (ii) for amplifying SARS-CoV-2 nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0050] Optionally, the forward and / or reverse nucleic acid amplification primers of each of nucleic acid amplification primer pairings (i) and (ii) hybridise specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, or the complement thereof.

[0051] Optionally, the forward and / or reverse nucleic acid amplification primers of each of nucleic acid amplification primer pairings (i) and (ii) hybridise specifically to nucleic acid sequence that is the complement of nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, or the complement thereof.

[0052] Optionally, the other human coronavirus nucleic acid is human coronavirus 229E, SARS, HKU1, MERS, OC43, and NL63 nucleic acid.P107173W001

[0053] 7

[0054] Optionally, the nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, comprises a contiguous nucleic acid sequence that is at least 19 nucleotides long.

[0055] Optionally, the nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid is nucleic acid sequence that is conserved in the ORFIab gene or the ORF8 gene of SARS-CoV-2.

[0056] Optionally, the forward nucleic acid amplification primer of SEQ ID NO:1 hybridises to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof.

[0057] Optionally, the forward nucleic acid amplification primer of SEQ ID NO:1 hybridises specifically to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof.

[0058] Optionally, the reverse nucleic acid amplification primer of SEQ ID NO:2 hybridises to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof.

[0059] Optionally, the reverse nucleic acid amplification primer of SEQ ID NO:2 hybridises specifically to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof.

[0060] Optionally, the forward nucleic acid amplification primer of SEQ ID NO:4 hybridises to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof.

[0061] Optionally, the forward nucleic acid amplification primer of SEQ ID NO:4 hybridises specifically to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof.

[0062] Optionally, the reverse nucleic acid amplification primer of SEQ ID NO:5 hybridises to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof.

[0063] Optionally, the reverse nucleic acid amplification primer of SEQ ID NO:5 hybridises specifically to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof.P107173W001

[0064] 8

[0065] Optionally, the method comprises use of forward and reverse nucleic acid amplification primer pairing (i), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:1, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:2, or the complement thereof.

[0066] Optionally, the method comprises use of forward and reverse nucleic acid amplification primer pairing (i), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:1, ora nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:2, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof.

[0067] Optionally, the method comprises use of forward and reverse nucleic acid amplification primer pairing (ii), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:4, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0068] Optionally, the method comprises use of forward and reverse nucleic acid amplification primer pairing (ii), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:4, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:5, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0069] Optionally, a method of the invention for determining whether a sample includes nucleic acid of SARS-CoV-2 comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using the forward and reverse nucleic acid amplification primer pairings (i) and (ii), wherein:

[0070] primer pairing (i) comprises a forward nucleic acid amplification primer comprising a nucleic acid sequence of SEQ ID NO:1, or the complement thereof, and a reverse nucleicP107173W001

[0071] 9

[0072] acid amplification primer comprising a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and

[0073] primer pairing (ii) comprises a forward nucleic acid amplification primer comprising a nucleic acid sequence of SEQ ID NO:4, or the complement thereof, and a reverse nucleic acid amplification primer comprising a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0074] Optionally, the method comprises use of the forward and reverse nucleic acid amplification primer pairings (i) and (ii).

[0075] Optionally, the method further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe. Optionally, the detector probe hybridises specifically to SARS-CoV-2 nucleic acid, or the complement thereof. Optionally, the detector probe hybridises to SARS-CoV-2 nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof. Optionally, the detector probe hybridises specifically to SARS-CoV-2 nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

[0076] Optionally, a detector probe hybridises to nucleic acid sequence of SARS-CoV-2, or the complement thereof, if it hybridises under stringent conditions to nucleic acid sequence of SARS-CoV-2, or the complement thereof.

[0077] Optionally, a product of the amplification reaction using primer pairing (i) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO:3, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof.

[0078] Optionally, the detector probe for use with primer pairing (i) comprises a nucleic acid sequence of SEQ ID NO:3, or the complement thereof.

[0079] Optionally, a product of the amplification reaction using primer pairing (ii) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO:6, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.P107173W001

[0080] 10

[0081] Optionally, the detector probe for use with primer pairing (ii) comprises a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0082] Optionally, the detector probe used to detect a product of the amplification reaction using primer pairing (i) or (ii) hybridises to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but is not conserved in other human coronavirus nucleic acid, or the complement thereof. Optionally, the detector probe used to detect a product of the amplification reaction using primer pairing (i) or (ii) hybridises specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but is not conserved in other human coronavirus nucleic acid, or the complement thereof.

[0083] Optionally, the other human coronavirus nucleic acid is human coronavirus 229E, SARS, HKU1, MERS, 0043, and NL63 nucleic acid.

[0084] Optionally, the nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, comprises a contiguous nucleic acid sequence that is at least 19 nucleotides long.

[0085] Optionally, the nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid is nucleic acid sequence that is conserved in the ORFIab gene or the ORF8 gene of SARS-CoV-2.

[0086] Optionally, the detector probe of SEQ ID NO:3 hybridises to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof. Optionally, the detector probe of SEQ ID NO:3 hybridises specifically to nucleic acid sequence that is conserved in the ORFIab gene of SARS-CoV-2, or the complement thereof.

[0087] Optionally, the detector probe of SEQ ID NO:6 hybridises to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof. Optionally, the detector probe of SEQ ID NO:6 hybridises specifically to nucleic acid sequence that is conserved in the ORF8 gene of SARS-CoV-2, or the complement thereof.

[0088] Detection of Influenza A

[0089] Primers and probes specific to Influenza A virus which hybridise to Matrix Protein (MP) and the polymerase protein 2 (PB2) genes have been designed.

[0090] Matrix protein 1 (M1) is the most abundant structural protein of influenza A virus playing a multifaceted role in viral uncoating, polymerase activity, vRNA transcription and replication,P107173W001

[0091] 11

[0092] and assembly and budding. The M1 protein not only interacts with host cells but also regulates viral morphogenesis, thereby influencing viral transmissibility and pathogenicity.

[0093] Polymerase protein 2 (PB2) is essential for viral transcription and replication by binding host cell pre-mRNA cap structures (cap-snatching) to initiate transcription.

[0094] According to the invention there is provided a method for determining whether a sample includes Influenza A nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:

[0095] i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: CAT TTT GGA CAA AGC GTC TA (SEQ ID NO:7), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:7, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: ACC RAT CCT GTC ACC TYT GAC (SEQ ID NO:8), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:8, or the complement thereof; and / or

[0096] ii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: ACT AAT TGA TGG CCA TYC GAA T (SEQ ID NO: 10); or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 10, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: TGA AAC GRA AAC GGG ACT CTA G (SEQ ID NO: 11), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:11, or the complement thereof.

[0097] Optionally, the method further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to Influenza A nucleic acid sequence that is conserved in Influenza A, or the complement thereof.

[0098] Optionally, a product of the amplification reaction using the primer pairing (i) for amplifying Influenza A nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: CCG TGC CCA GTG AGC G (SEQ IDP107173W001

[0099] 12

[0100] NO:9), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:9, or the complement thereof;

[0101] a product of the amplification reaction using the primer pairing (ii) for amplifying Influenza A nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: ACA GCC AGA CAG CGA CCA A (SEQ ID NO: 12), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:12, or the complement thereof.

[0102] Detection of Influenza B

[0103] Primers and probes specific to Influenza B virus which hybridise to Non-structural Protein (NS) and the polymerase protein (PB2) genes have been designed.

[0104] The Non-structural (NS) Protein is essential for efficient viral growth and antagonizes Beta Interferon induction.

[0105] The phosphoprotein (P) plays critical roles in regulating RNA replication and transcription through its interactions with multiple proteins.

[0106] According to the invention there is provided a method for determining whether a sample includes Influenza B nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:

[0107] i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: CTC GAA GAG TGA RTT GAG GAT (SEQ ID NO:13), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 13, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: TGG AAG GCT TGT TGC TAA (SEQ ID NO:14), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 14, or the complement thereof; and / or

[0108] ii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GCA TTT CCT TGG TGA GAG AG (SEQ ID NO:16); or a nucleic acid sequence that has atP107173W001

[0109] 13

[0110] least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 16, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: AGA CTT GAC AAY GCC ACT T (SEQ ID NO:17), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 17, or the complement thereof.

[0111] Optionally, the method further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to Influenza B nucleic acid sequence that is conserved in Influenza B, or the complement thereof.

[0112] Optionally, a product of the amplification reaction using primer the pairing (i) for amplifying Influenza B nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: TAG AGT GGA GGA TGA AGA AGA TGG (SEQ ID NO: 15), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 15, or the complement thereof;

[0113] a product of the amplification reaction using the primer pairing (ii) for amplifying Influenza B nucleic acid is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: ACT TTT GGC CCA GTT GAA AG (SEQ ID NO:18), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:18, or the complement thereof.

[0114] Detection of RSV

[0115] Primers and probes specific to RSV type A and RSV type B which hybridise to the Phosphoprotein (P) gene have been designed.

[0116] The phosphoprotein (P) plays critical roles in regulating RNA replication and transcription through its interactions with multiple proteins.

[0117] According to the invention there is provided a method for determining whether a sample includes Respiratory syncytial virus (RSV) nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by anP107173W001

[0118] 14

[0119] amplification reaction using the following forward and reverse nucleic acid amplification primer pairings:

[0120] a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GGA TTG AGA GAC ACT TCA TCT G (SEQ ID NO: 19), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 19, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: GGT TGG TYT AAG AGA AGA AAT GA (SEQ ID NQ:20), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NQ:20, or the complement thereof.

[0121] Optionally, the method further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to RSV nucleic acid sequence that is conserved in RSV type A and RSV type B, or the complement thereof.

[0122] Optionally, a product of the amplification reaction using the primer pairing for amplifying RSV nucleic acid is detected by hybridising the product to one or more nucleic acid detector probes comprising a nucleic acid sequence of: AGC TAT GGC AAG ACT CAG GAA TG (SEQ ID NO:21), or a nucleic acid sequence of: CTA TGG CAA GAC TTA GGA ATG AGG (SEQ ID NO:22), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 21 and SEQ ID NO:22, or the complement thereof.

[0123] Multiplex detection of SARS-CoV-2, Influenza A, Influenza B and RSV

[0124] The method of the invention may be used as a multiplex to detect the presence of 1 , 2, 3, 4 or more different viruses simultaneously as discussed herein. In such multiplex detection a simultaneous amplification may be carried out using 1, 2, 3, 4, 5, 6, 7, 8 or more pairs of oligonucleotide primers together, for example in one or more amplification vessels and / or one or more amplification compositions and / or one or more sets of amplification cycles. The amplification may result in amplified nucleic acid from 1, 2, 3, 4 or more different viruses as discussed herein. These amplified nucleic acids may be present in one or more compositions which are the product of the amplification.P107173W001

[0125] 15

[0126] According to the invention there is provided a method for determining whether a sample includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and / or Influenza A and / or Influenza B and / or Respiratory syncytial virus (RSV) nucleic acid, which comprises carrying out the detection method above for SARS-CoV-2 and / or for Influenza A and / or Influenza B and / or RSV, respectively.

[0127] Optionally, the amplification reaction comprises a polymerase chain reaction (PCR) amplification reaction. Optionally, the PCR amplification reaction is a real-time (rt) PCR.

[0128] Nucleic acid may be derived from nucleic acid of the sample, for example by reverse transcribing SARS-CoV-2 RNA, and / or Influenza A RNA, and / or Influenza B RNA, and / or RSV RNA of the sample and amplifying a product of the reverse transcription by an amplification reaction using one or more of the forward and reverse nucleic acid amplification primer pairings above for SARS-CoV-2, Influenza A, Influenza B and RSV, respectively.

[0129] Optionally, the detector probe comprises a fluorescent label. Suitable fluorescent labels are described below and include ATTO fluorescent dyes.

[0130] Optionally, the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label, Optionally, wherein the detector probe is a hydrolysis probe, or a molecular beacon probe which includes nucleotide sequence which has complementarity to itself.

[0131] Optionally, the sample is a biological sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV. Optionally, the sample is a nasopharyngeal or a throat swab sample. The sample is generally contacted with reagents as described herein, for example primer pairs and probes as described herein.

[0132] Optionally, the method further comprises isolating nucleic acid of the sample before reverse transcribing and amplifying the isolated nucleic acid.

[0133] Oligonucleotides

[0134] According to the invention there is provided an oligonucleotide, which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-22, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-22, or the complement thereof.

[0135] Optionally, the oligonucleotide is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.P107173W001

[0136] 16

[0137] According to the invention there is provided one or more pairs of oligonucleotide primers for determining whether a sample includes SARS-CoV-2 nucleic acid, which comprises:

[0138] i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:1 , or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:2, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / or

[0139] ii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:4; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:5, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0140] The first and second primer of a pair of oligonucleotide primers of the invention may be used to detect for SARS-CoV-2 nucleic acid.

[0141] Optionally, the first and / or second primer of a pair of oligonucleotide primers of the invention hybridise specifically under stringent conditions to SARS-CoV-2 nucleic acid.

[0142] Optionally, the one or more pairs of oligonucleotide primers comprises:

[0143] a) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / or

[0144] b) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0145] Optionally, each primer is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.P107173W001

[0146] 17

[0147] According to the invention there is provided a set of oligonucleotides for amplifying SARS-CoV-2 nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:

[0148] a pair of oligonucleotide primers for determining whether a sample includes SARS-CoV-2 nucleic acid according to the invention; and

[0149] a detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

[0150] Optionally, the set of oligonucleotides comprises:

[0151] a pair of primers according to primer pair embodiment (i) or (a) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, ora nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / or

[0152] a pair of primers according to primer pair embodiment (ii) or (b) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, ora nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0153] Optionally, the set of oligonucleotides comprises:

[0154] a pair of primers according to primer pair embodiment (i) or (a) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / or

[0155] a pair of primers according to primer pair embodiment (ii) or (b) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0156] Optionally, the set of oligonucleotides comprises:

[0157] a pair of primers according to primer pair embodiment (a) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / orP107173W001

[0158] 18

[0159] a pair of primers according to primer pair embodiment (b) above; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0160] Optionally, the set of oligonucleotides comprises:

[0161] i) the pair of oligonucleotide primers (i) for amplifying SARS-CoV-2 nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / or

[0162] ii) the pair of oligonucleotide primers (ii) for amplifying SARS-CoV-2 nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0163] Optionally, the detector probe hybridises under stringent conditions to SARS-CoV-2 nucleic acid.

[0164] According to the invention there is provided a pair of oligonucleotide primers for determining whether a sample includes Influenza A nucleic acid, which comprises:

[0165] i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:7, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:7, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:8, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:8, or the complement thereof; and / or

[0166] ii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO: 10; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 10, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:11, ora nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,P107173W001

[0167] 19

[0168] or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:11, or the complement thereof.

[0169] The first and second primer of a pair of oligonucleotide primers of the invention may be used to detect for Influenza A nucleic acid.

[0170] Optionally, the first and / or second primer of a pair of oligonucleotide primers of the invention hybridise specifically under stringent conditions to Influenza A nucleic acid.

[0171] Optionally, each primer is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0172] According to the invention there is provided a set of oligonucleotides for amplifying Influenza A nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:

[0173] a pair of oligonucleotide primers for determining whether a sample includes Influenza A nucleic acid according to the invention; and

[0174] a detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in Influenza A, or the complement thereof.

[0175] Optionally, the set of oligonucleotides comprises:

[0176] i) the pair of oligonucleotide primers (i) for amplifying Influenza A nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:9, ora nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:9, or the complement thereof; and / or

[0177] ii) the pair of oligonucleotide primers (ii) for amplifying Influenza A nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:12, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 12, or the complement thereof.

[0178] Optionally, the detector probe hybridises under stringent conditions to Influenza A nucleic acid.

[0179] According to the invention there is provided a pair of oligonucleotide primers for determining whether a sample includes Influenza B nucleic acid, which comprises:P107173W001

[0180] 20

[0181] i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:13, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 13, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:14, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 14, or the complement thereof; and / or

[0182] ii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:16; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 16, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 17, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 17, or the complement thereof.

[0183] The first and second primer of a pair of oligonucleotide primers of the invention may be used to detect for Influenza B nucleic acid.

[0184] Optionally, the first and / or second primer of a pair of oligonucleotide primers of the invention hybridise specifically under stringent conditions to Influenza B nucleic acid.

[0185] Optionally, each primer is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0186] According to the invention there is provided a set of oligonucleotides for amplifying Influenza B nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:

[0187] a pair of oligonucleotide primers for determining whether a sample includes Influenza B nucleic acid according to the invention; and

[0188] a detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in Influenza B, or the complement thereof.

[0189] Optionally, the set of oligonucleotides comprises:

[0190] i) the pair of oligonucleotide primers (i) for amplifying Influenza B nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:15, or a nucleic acidP107173W001

[0191] 21

[0192] sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 15, or the complement thereof; and / or

[0193] ii) the pair of oligonucleotide primers (ii) for amplifying Influenza B nucleic acid; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:18, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 18, or the complement thereof.

[0194] Optionally, the detector probe hybridises under stringent conditions to Influenza B nucleic acid.

[0195] According to the invention there is provided a pair of oligonucleotide primers for determining whether a sample includes RSV nucleic acid, which comprises:

[0196] a first primer, which comprises a nucleic acid sequence of SEQ ID NO: 19, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 19, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NQ:20, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NQ:20, or the complement thereof.

[0197] The first and second primer of a pair of oligonucleotide primers of the invention may be used to detect for RSV nucleic acid.

[0198] Optionally, the first and / or second primer of a pair of oligonucleotide primers of the invention hybridise specifically under stringent conditions to RSV nucleic acid.

[0199] Optionally, each primer is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0200] According to the invention there is provided a set of oligonucleotides for amplifying RSV nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:

[0201] a pair of oligonucleotide primers for determining whether a sample includes RSV nucleic acid according to the invention; andP107173W001

[0202] 22

[0203] a detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in RSV, or the complement thereof.

[0204] Optionally, the set of oligonucleotides comprises:

[0205] the pair of oligonucleotide primers for amplifying RSV nucleic acid; and one or more detector probes comprising a nucleic acid sequence selected from SEQ ID NO:21 and SEQ ID NO:22, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:21 and SEQ ID NO:22, or the complement thereof.

[0206] Optionally, the detector probe hybridises under stringent conditions to RSV nucleic acid.

[0207] Optionally, the detector probe is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0208] Optionally, the detector probe is labelled with a fluorescent label.

[0209] Optionally, the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0210] Suitable fluorescent labels for use according to the invention are discussed below and include ATTO fluorescent dyes.

[0211] Optionally, the first and second primer, and the detector probe, comprise respective nucleic acid sequences according to one or more combinations of the first and second primer, and the detector probe, shown in the table below, or nucleic acid sequences which have at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along their entire length with such sequences:

[0212] Combination First primer Second primer Detector probe 1 SEQ ID NO:1 SEQ ID NO:2 SEQ ID NO:3 2 SEQ ID NO:4 SEQ ID NO:5 SEQ ID NO:6 3 SEQ ID NO:7 SEQ ID NO:8 SEQ ID NO:9 4 SEQ ID NO:10 SEQ ID NO:11 SEQ ID NO:12 5 SEQ ID NO:13 SEQ ID NO:14 SEQ ID NO:15 6 SEQ ID NO:16 SEQ ID NO:17 SEQ ID NO:18 7 SEQ ID NO:19 SEQ ID NO:20 SEQ ID NO:21 and / or

[0213]

[0214] SEQ ID NO:22P107173W001

[0215] 23

[0216] Optionally, the oligonucleotide, the pair of oligonucleotide primers, or the set of oligonucleotides according to the invention are each an oligonucleotide which is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0217] Conserved sequences may be identified by homology search, using tools such as BLAST, HMMER and Infernal. Homology search tools may take an individual nucleic acid sequence as input, or use statistical models generated from multiple sequence alignments of known related sequences. Statistical models such as profile-HMMs, and RNA covariance models which also incorporate structural information, can be helpful when searching for more distantly related sequences. Input sequences are then aligned against a database of sequences from related individuals or other species. The resulting alignments are then scored based on the number of matching bases, and the number of gaps or deletions generated by the alignment. Acceptable conservative substitutions may be identified using substitution matrices such as PAM and BLOSLIM. Highly scoring alignments are assumed to be from homologous sequences. The conservation of a sequence may then be inferred by detection of highly similar homologs over a broad phylogenetic range.

[0218] Optionally, conserved SARS-CoV-2, Influenza A, Influenza B and RSV nucleic acid is nucleic acid comprising nucleic acid sequence that includes up to 2 mismatches per 20 nucleotides compared with a reference SARS-CoV-2, Influenza A, Influenza B or RSV nucleic acid sequence, respectively.

[0219] Optionally, conserved SARS-CoV-2, Influenza A, Influenza B and RSV nucleic acid is nucleic acid comprising nucleic acid sequence that includes up to 1 mismatch per 20 nucleotides compared to a reference SARS-CoV-2, Influenza A, Influenza B or RSV nucleic acid sequence, respectively.

[0220] Optionally, conserved SARS-CoV-2, Influenza A, Influenza B and RSV nucleic acid is nucleic acid comprising nucleic acid sequence that is identical to a reference SARS-CoV-2, Influenza A, Influenza B or RSV nucleic acid sequence, respectively.

[0221] Multiple sequence alignments can be used to visualise conserved sequences. The CLUSTAL format includes a plain-text key to annotate conserved columns of the alignment, denoting conserved sequence (*), conservative mutations (:), semi-conservative mutations (.), and non-conservative mutations ( ). Software such as MacVector can be used to perform multiple sequence alignments.

[0222] Optionally, a nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, or the complement thereof, if it hybridisesP107173W001

[0223] 24

[0224] under stringent conditions to the conserved SARS-CoV-2 nucleic acid sequence, or the complement thereof, but not other human coronavirus nucleic acid, or the complement thereof.

[0225] Optionally, a nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in Influenza A nucleic acid, or the complement thereof, if it hybridises under stringent conditions to the conserved Influenza A nucleic acid sequence, or the complement thereof, but not other human Influenza virus nucleic acid, or the complement thereof.

[0226] Optionally, a nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in Influenza B nucleic acid, or the complement thereof, if it hybridises under stringent conditions to the conserved Influenza B nucleic acid sequence, or the complement thereof, but not other human Influenza virus nucleic acid, or the complement thereof.

[0227] Optionally, a nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in RSV nucleic acid, or the complement thereof, if it hybridises under stringent conditions to the conserved RSV nucleic acid sequence, or the complement thereof, but not other human Respiratory virus nucleic acid, or the complement thereof.

[0228] The stringency of hybridisation is influenced by conditions such as temperature, salt concentration, ionic strength and hybridisation buffer composition. Generally, low stringency conditions are selected to be about 30°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Medium stringency conditions are when the temperature is 20°C. below Tm, and high stringency conditions are when the temperature is 10°C below Tm. The Tmis the temperature under defined ionic strength and pH, at which 50% of the target sequence hybridises to a perfectly matched primer or probe. The Tmis dependent upon the solution conditions and the base composition and length of the probe. For example, longer sequences hybridise specifically at higher temperatures. The maximum rate of hybridisation is obtained from about 16°C up to 32°C below Tm. The presence of monovalent cations in the hybridisation solution reduce the electrostatic repulsion between the two nucleic acid strands thereby promoting hybrid formation; this effect is visible for sodium concentrations of up to 0.4M (for higher concentrations, this effect may be ignored). Formamide reduces the melting temperature of DNA-DNA and DNA-RNA duplexes with 0.6 to 0.7°C for each percent formamide, and addition of 50% formamide allows hybridisation to be performed at 30 to 45°C, though the rate of hybridisation will be lowered. Base pair mismatches reduce the hybridisation rate and the thermal stability of the duplexes. On average and for large probes, the Tmdecreases about 1°C per % base mismatch. The Tmmay be calculated using the following equations, depending on the types of hybrids:P107173W001

[0229] 25

[0230] 1) DNA-DNA hybrids (Meinkoth and Wahl, Anal. Biochem., 138: 267-284, 1984):

[0231] Tm=81.5° C +16.6xlogio[Na+]a+0.41x%[G / Cb]-500x [Lc]-1-0.61x% formamide;

[0232] 2) DNA-RNA or RNA-RNA hybrids:

[0233] Tm=79.8°C+18.5(logio[Na+]a)+0.58(%G / Cb)+11.8(%G / Cb)2-820 / Lc;

[0234] 3) oligo-DNA or oligo-RNAs hybrids:

[0235] For <20 nucleotides: Tm=2(ln);

[0236] For 20-35 nucleotides: Tm=22+1.46(ln);

[0237] aor for other monovalent cation, but only accurate in the 0.01-0.4 M range.

[0238] bonly accurate for % GO in the 30% to 75% range.

[0239] cL = length of duplex in base pairs.

[0240] doligo, oligonucleotide; 1n, = effective length of primer=2x (no. of G / C)+(no. of NT).

[0241] Besides the hybridisation conditions, specificity of hybridisation typically also depends on the function of post-hybridisation washes. To remove background resulting from non-specific hybridisation, samples are washed with dilute salt solutions. Critical factors of such washes include the ionic strength and temperature of the final wash solution: the lower the salt concentration and the higher the wash temperature, the higher the stringency of the wash. Wash conditions are typically performed at or below hybridisation stringency. A positive hybridisation gives a signal that is at least twice of that of the background. Generally, suitable stringent conditions for nucleic acid hybridisation assays or gene amplification detection procedures are as set forth above. More or less stringent conditions may also be selected. The skilled artisan is aware of various parameters which may be altered during washing and which will either maintain or change the stringency conditions.

[0242] For example, typical stringent conditions (also referred to as high stringency hybridisation conditions) for DNA hybrids longer than 50 nucleotides encompass hybridisation at 65°C in 1xSSC or at 42°C in 1xSSC and 50% formamide, followed by washing at 65°C in 0.3xSSC. The length of the hybrid is the anticipated length for the hybridising nucleic acid. When nucleic acids of known sequence are hybridised, the hybrid length may be determined by aligning the sequences and identifying the conserved regions described herein. 1xSSC isP107173W001

[0243] 26

[0244] 0.15M NaCI and 15 mM sodium citrate; the hybridisation solution and wash solutions may additionally include 5xDenhardt’s reagent, 0.5-1.0% SDS, 100 .g / ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate.

[0245] For the purposes of defining the level of stringency, reference can be made to Sambrook et al. (2001) Molecular Cloning: a laboratory manual, 3rd Edition, Cold Spring Harbor Laboratory Press, CSH, New York or to Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989 and yearly updates).

[0246] Optionally, the amplification reaction comprises a polymerase chain reaction (PCR) amplification reaction. Optionally, the PCR amplification reaction is a real-time (rt) PCR.

[0247] Nucleic acid may be derived from nucleic acid of the sample, for example by reverse transcribing nucleic acid of the sample and amplifying a product of the reverse transcription by a nucleic acid amplification reaction using the forward and reverse nucleic acid amplification primers.

[0248] Optionally, the method further comprises reverse transcribing RNA of the sample and amplifying a product of the reverse transcription by an amplification reaction using one or more of the forward and reverse nucleic acid amplification primer pairings.

[0249] Optionally, the method further comprises isolating nucleic acid of the sample before reverse transcribing and amplifying the isolated nucleic acid.

[0250] Optionally, the detector probe comprises a fluorescent label. Any suitable fluorescent label may be used. Suitable examples include ATTO fluorescent dyes. ATTO fluorescent dyes are discussed in more detail below. Optionally, the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0251] Optionally, the detector probe is a hydrolysis probe, which includes a quencher. Alternatively, Optionally, the detector probe is a molecular beacon probe, which includes nucleotide sequence which has complementarity to itself (so the probe can form a stem-loop structure), and a quencher. Hydrolysis probes and molecular beacon probes are discussed below. Suitable quenchers for ATTO dyes are provided below.

[0252] Optionally, the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0253] Optionally, the detector probe is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.P107173W001

[0254] 27

[0255] Detection of PCR products using real-time PCR instruments is widely known. Particularly, probe-based quantitative detection is widely used as it provides an accurate and reproducible analysis. Probe-based analysis offers the least background fluorescence as compared to dye-based chemistries.

[0256] Several different types of PCR probes are commercially available. Popular PCR probes include hydrolysis probes, Molecular Beacon probes.

[0257] Hydrolysis probes are labelled probes used to target specific sequences by complementation. They are comprised of an oligonucleotide which has complementarity to the target nucleic acid sequence, a fluorescent reporter, and a quencher, wherein the fluorescence emitted by the reporter is indicative of presence of target sequence.

[0258] The fluorescent reporter fluoresces when it is spatially separated from the quencher on the probe. The quencher is attached to the oligonucleotide and absorbs excitation energy from the fluorophore. It quenches the fluorescence emitted by the fluorophore when they are in proximity, which occurs when the probe is bound to the target nucleic acid (Figure 4a).

[0259] During primer extension, the DNA polymerase initiates polymerization and executes 5' — > 3' exonuclease activity on the oligonucleotide of the probe, and the fluorescent reporter and quencher are released from the probe. The reporter and quencher are separated, and the reporter emits fluorescence.

[0260] Similarly, molecular beacon probes consist of a complementary oligonucleotide, a fluorescent reporter, and a quencher. A molecular beacon probe is designed so the oligonucleotide has complementarity to itself that leads to the formation of a stem and loop structure. When the probe is not bound to the target sequence, the quencher and reporter are bound to each end of the oligo hairpin, and the quencher and reporter are in close range and the fluorescence is quenched. When the probe hybridises to the target nucleic acid, the stem and loop structure is opened, separating the reporter from the quencher, and the reporter fluoresces (Figure 4b).

[0261] Unlike the hydrolysis probes, the reporter is not removed from the probe by the exonuclease activity of the polymerase, and so a DNA polymerase lacking 5' exonuclease activity can be used.

[0262] Optionally, the sample is a biological sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV. Optionally,P107173W001

[0263] 28

[0264] the sample is a nasopharyngeal or a throat swab sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV.

[0265] Optionally, the method is an in vitro method.

[0266] Polymerase chain reaction (PCR)

[0267] Optionally, a method of the invention comprises a polymerase chain reaction (PCR) amplification reaction. Optionally, the PCR amplification reaction is a real-time (rt) PCR.

[0268] Nucleic acid may be derived from nucleic acid of the sample, for example by reverse transcribing RNA of the sample, and amplifying a product of the reverse transcription by a nucleic acid amplification reaction using the forward and reverse nucleic acid amplification primers.

[0269] Optionally, a method of the invention further comprises reverse transcribing RNA of the sample and amplifying a product of the reverse transcription by an amplification reaction using forward and reverse nucleic acid amplification primer pairings of the invention.

[0270] Any suitable method of nucleic acid amplification using a forward and reverse nucleic acid amplification primer may be used in methods of the invention. However, it is particularly envisaged that real-time PCR nucleic acid amplification is used in methods of the invention. Suitable methods of real-time PCR nucleic acid amplification are known to the skilled person. Optionally, the real-time PCR nucleic acid amplification reaction reverse transcribes an RNA template into cDNA before the transcribed cDNA is amplified by PCR. Such methods involve reverse transcriptase (RT) and RNase activities. A review of real-time PCR is provided in Real-Time PCR Handbook, Life Technologies (URL: https: / / www.gene-quantification.de / real-time-pcr-handbook-life-technologies-update-flr.pdf), Withrow and MacEwen's Small Animal Clinical Oncology (Fifth Edition), 2013, page 131-142, and in Mackay etal, Nucleic Acids Research, vol 30(6): 1292-1305 (2002).

[0271] Nucleic acid amplification reactions such as real-time PCR offer a straightforward means for detecting target nucleic acid specifically and with high sensitivity. Fewer reagents are required than, for example, isothermal amplification methods such as NASBA or LAMP. Real-time PCR provides the ability to monitor the progress of the PCR reaction as it occurs in real time. Real-time PCR provides the ability to measure the amount of amplicon at each cycle which allows highly accurate quantification of the amount of starting material in samples. Furthermore, amplification and detection can occur in a single tube, wherein theP107173W001

[0272] 29

[0273] change in the fluorescence over the course of the reaction is measured by an instrument that combines thermal cycling with fluorescence detection and measurement.

[0274] A real-time reverse transcriptase PCR (also known as rt-qPCR) nucleic acid amplification reaction suitable for use in the method of the invention is described below, with reference to Figure 2.

[0275] A poly(T) DNA primer hybridises to the poly(A) tail of the SARS-CoV-2 mRNA at the 3’ end, priming reverse transcription by an RNA-dependent DNA polymerase which extends the primer in the 5’ to 3’ direction to synthesise a complementary DNA (cDNA) copy of the RNA target (direction with respect to the newly synthesised cDNA). A DNA / RNA duplex-specific ribonuclease digests the RNA of the RNA-cDNA hybrid. cDNA can also be prepared from mRNA using gene specific primers or random hexamer primers.

[0276] The forward primer comprises nucleic acid sequence complementary to a portion of the cDNA. The forward primer anneals to the cDNA, which is used as a primer to allow a DNA-dependent DNA polymerase to synthesise a second copy of the DNA molecule, which extends in the 5’ to 3’ direction. Single-stranded cDNA is thus converted into double-stranded DNA, which then functions as a template for a cyclic phase of the reaction, using the forward and reverse nucleic acid amplification primers. The forward and reverse primers hybridise to their complementary sequence on either strand of the dsDNA molecule after strand denaturation (the reverse nucleic acid amplification primer anneals to the opposite DNA strand as the forward nucleic acid amplification primer). The primers are then extended by DNA polymerase, forming two dsDNA molecules. The cycle repeats, forming exponential amounts of nucleic acid molecules.

[0277] If a reverse transcriptase (RT) enzyme is used for RNA-dependent DNA polymerisation, the enzyme also comprises ribonuclease H (RNase H) activity, and so can be used for cDNA formation and RNA degradation. Suitable RT enzymes include Moloney murine leukemia virus (M-MLV) reverse transcriptase and Avian myeloblastosis virus (AMV) reverse transcriptase. If an enzyme does not possess RNase activity, an RNase H may be added for better qPCR efficiency. For RT-qPCR, it is ideal to choose a reverse transcriptase with high thermal stability, because this allows cDNA synthesis to be performed at higher temperatures, helping ensure successful transcription of RNA with high levels of secondary structure, while maintaining their full activity throughout the reaction to help produce higher cDNA yields

[0278] DNA synthesis and PCR can be performed in a single reaction vessel in a common reaction buffer. Major advantages of one-step reaction include minimal sample handling, reducedP107173W001

[0279] 30

[0280] bench time, and closed-tube reactions, reducing chances for pipetting errors and crosscontamination.

[0281] There are three major steps that make up each cycle of the cyclic phase in a real-time PCR reaction (when a dsDNA molecule is used as a template). Reactions are generally run for 40 cycles.

[0282] 1. Denaturation: High temperature incubation is used to denature double-stranded DNA into single strands and loosen secondary structure in single-stranded DNA. The denaturation time can be increased if template GC content is high.

[0283] 2. Annealing: Forward and reverse nucleic acid amplification primers anneal to complementary sequences, so an appropriate temperature is used that is based on the calculated melting temperature (Tm) of the primers (5°C below the Tm of the primer).

[0284] 3. Extension: At70-72°C, the activity of the DNA polymerase is optimal, and primer extension occurs at rates of up to 100 bases per second. When an amplicon in real-time PCR is small, this step is often combined with the annealing step using 60°C as the temperature.

[0285] The forward and reverse nucleic acid amplification primers comprise nucleic acid sequence complementary to a portion of the cDNA, or nucleic acid sequence which allows the primers to hybridise specifically under stringent conditions to target nucleic acid.

[0286] Examples of suitable reagents for carrying out reverse transcription of RNA, and for amplification of a product of the reverse transcription, are given in Real-Time PCR Handbook, Life Technologies (supra), and include, for example, the following enzyme activities: an RNA-dependent DNA polymerase, a DNA-dependent DNA polymerase (such as Taq polymerase), and a DNA / RNA duplex-specific ribonuclease.

[0287] It will be appreciated that in addition to the required enzyme activities, it will also be necessary to provide appropriate nucleotide triphosphates - deoxyribonucleotide triphosphates (dNTPs, i.e. dATP, dGTP, dCTP, and dTTP), appropriate primers for specific amplification of the target nucleic acid, a suitable buffer for carrying out the amplification reaction, and any necessary cofactors (for example magnesium ions) required by the enzyme activities. Examples of suitable buffers include Tris-HCI, HEPES, or acetate buffer. A suitable salt may be provided, such as potassium chloride or sodium chloride. Suitable concentrations of these components may readily be determined by the skilled person. Suitable dNTP concentrations are typically in the range 0.25-5mM dNTP, or 0.5-2.5mM. Suitable magnesium ion concentrations are typically in the range 3-15mM, preferably 3-6mM.P107173W001

[0288] 31

[0289] The stringency of hybridisation is influenced by conditions such as temperature, salt concentration, ionic strength and hybridisation buffer composition. Generally, low stringency conditions are selected to be about 30°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Medium stringency conditions are when the temperature is 20°C. below Tm, and high stringency conditions are when the temperature is 10°C below Tm. The Tmis the temperature under defined ionic strength and pH, at which 50% of the target sequence hybridises to a perfectly matched primer or probe. The Tmis dependent upon the solution conditions and the base composition and length of the probe. For example, longer sequences hybridise specifically at higher temperatures. The maximum rate of hybridisation is obtained from about 16°C up to 32°C below Tm. The presence of monovalent cations in the hybridisation solution reduces the electrostatic repulsion between the two nucleic acid strands thereby promoting hybrid formation; this effect is visible for sodium concentrations of up to 0.4M (for higher concentrations, this effect may be ignored). Formamide reduces the melting temperature of DNA-DNA or DNA-RNA duplexes with 0.6 to 0.7°C for each percent formamide, and addition of 50% formamide allows hybridisation to be performed at 30 to 45°C, though the rate of hybridisation will be lowered. Base pair mismatches reduce the hybridisation rate and the thermal stability of the duplexes. On average and for large probes, the Tmdecreases about 1°C per % base mismatch. The Tmmay be calculated using the following equations, depending on the types of hybrids:

[0290] 1) DNA-DNA hybrids (Meinkoth and Wahl, Anal. Biochem., 138: 267-284, 1984):

[0291] Tm=81.5° C.+16.6xlogio[Na+]a+0.41x%[G / Cb]-500x [Lc]-1-0.61x% formamide;

[0292] 2) DNA-RNA or RNA-RNA hybrids:

[0293] Tm=79.8°C+18.5(logio[Na+]a)+0.58(%G / Cb)+11.8(%G / Cb)2-820 / Lc;

[0294] 3) oligo-DNA or oligo-RNAs hybrids:

[0295] For <20 nucleotides: Tm=2(ln);

[0296] For 20-35 nucleotides: Tm=22+1.46(ln);

[0297] aor for other monovalent cation, but only accurate in the 0.01-0.4 M range.

[0298] bonly accurate for % GO in the 30% to 75% range.P107173W001

[0299] 32

[0300] L = length of duplex in base pairs.

[0301] doligo, oligonucleotide; 1n, = effective length of primer=2x (no. of G / C)+(no. of NT).

[0302] Besides the hybridisation conditions, specificity of hybridisation typically also depends on the function of post-hybridisation washes. To remove background resulting from non-specific hybridisation, samples are washed with dilute salt solutions. Critical factors of such washes include the ionic strength and temperature of the final wash solution: the lower the salt concentration and the higher the wash temperature, the higher the stringency of the wash. Wash conditions are typically performed at or below hybridisation stringency. A positive hybridisation gives a signal that is at least twice of that of the background. Generally, suitable stringent conditions for nucleic acid hybridisation assays or gene amplification detection procedures are as set forth above. Stringent conditions may also be selected. The skilled artisan is aware of various parameters which may be altered during washing and which will either maintain or change the stringency conditions.

[0303] For example, typical stringent conditions (also referred to as high stringency hybridisation conditions) for DNA hybrids longer than 50 nucleotides encompass hybridisation at 65°C in 1xSSC or at 42°C in 1xSSC and 50% formamide, followed by washing at 65°C in 0.3xSSC. The length of the hybrid is the anticipated length for the hybridising nucleic acid. When nucleic acids of known sequence are hybridised, the hybrid length may be determined by aligning the sequences and identifying the conserved regions described herein. 1xSSC is 0.15M NaCI and 15 mM sodium citrate; the hybridisation solution and wash solutions may additionally include 5xDenhardt’s reagent, 0.5-1.0% SDS, 100 .g / ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate.

[0304] For the purposes of defining the level of stringency, reference can be made to Sambrook et al. (2001) Molecular Cloning: a laboratory manual, 3rd Edition, Cold Spring Harbor Laboratory Press, CSH, New York or to Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989 and yearly updates).

[0305] The sample may comprise nucleic acid, for example nucleic acid from viruses present in the subject. The sample may comprise a virus which is present in the subject, such as any virus mentioned herein. The sample is typically from a human subject.

[0306] Optionally, the sample is a biological sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV. Optionally,P107173W001

[0307] 33

[0308] the sample is a nasopharyngeal or a throat swab sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV.

[0309] Isolation of nucleic acid

[0310] Optionally, the method further comprises isolating nucleic acid of the sample before reverse transcribing RNA of the sample present in the isolated nucleic acid.

[0311] Many suitable methods for isolation of nucleic acid are known to the skilled person. Some methods use chaotropic agents, such as guanidinium thiocyanate, and organic solvents to lyse cells, and denature proteins. For example, Boom et al. (Journal of Clinical Microbiology, 1990, Vol. 28(3): 495-503) describes methods in which a sample is contacted with silica particles in the presence of a lysis / binding buffer containing guanidinium thiocyanate. Released nucleic acid binds to the silica particles, which are then washed with a wash buffer containing guanidinium thiocyanate, then with ethanol, and then acetone. The bound nucleic acid is subsequently eluted in an aqueous low salt buffer (Tris-HCI, EDTA, pH 8.0).

[0312] Some methods avoid the requirement for chaotropic salts and organic solvents. For example, Hourfar et al. (Clinical Chemistry, 2005, 51(7): 1217-1222) describes methods in which a sample is mixed with magnetic silica particles in the presence of a lysis / binding buffer containing a kosmotropic salt (ammonium sulphate) before addition of proteinase K. Following separation, the magnetic particles are washed with wash buffer containing proteinase K, and eluted in elution buffer (Tris-HCI, pH 8.5) at 800C. Other suitable methods are described in WO 2010 / 015835.

[0313] Isolation of nucleic acid may be carried out using conventional binding buffers and / or elution buffers for use with a solid phase that is able to bind the nucleic acid in the presence of binding buffer at a first pH, and from which the nucleic acid can be eluted at a second pH.

[0314] Optionally, the solid phase comprises an ionisable group, which changes charge according to the ambient conditions. The pKa of the ionisable group is appropriate to the conditions at which it is desired to bind nucleic acid to and release nucleic acid from the solid phase. Generally, nucleic acid will bind to the solid phase at a pH below or roughly equal to the pKa and will be released at a higher pH (usually above the pKa). Suitable solid phases for binding a nucleic acid at a first pH, and elution of bound nucleic acid at a second pH that is higher than the first pH, are well known to those of ordinary skill in the art. For example, at the first pH the solid phase may comprise a positive charge, and at the second pH the solid phase may have a less positive, neutral, or negative charge. Alternatively, or additionally, at the first pH the solid phase may comprise a neutral or less negative charge, and at the second pHP107173W001

[0315] 34

[0316] the solid phase may have a negative or more negative charge. Such changes in charge allow the nucleic acid to be adsorbed to the solid phase at the first pH and released at the second pH.

[0317] For example, the solid phase may comprise a negatively ionisable group with a pKa between the first and second pH. Nucleic acid will bind to the solid phase when the solid phase is neutral or less negatively charged and will be released when the solid phase is negatively or more negatively charged. Alternatively, or additionally, the solid phase may comprise a positively ionisable group with a pKa between the first and second pH. Nucleic acid will bind to the solid phase when the solid phase is positively charged and will be released when the solid phase is neutral or less positively charged.

[0318] Examples of solid phases that may be used for extraction of nucleic acid include solid phases that comprise inorganic oxides, such as silica or glass (for example, as described in Boom et al, or Hourfar et al), or aluminium oxide, sugar polymers, or charge-switch materials (for example, as described in WO 02 / 48164).

[0319] The solid phase may be in any suitable form, for example comprising a membrane, gel, or particles, for example magnetic particles. Silica membrane or gel, and magnetic silica particles are preferred examples. Silica membrane is particularly preferred. This is less expensive than magnetic silica particles (used for example by Hourfar, et al.) and does not require refrigerated storage, unlike magnetic silica particles.

[0320] The solid phase may be a solid phase to which binding of nucleic acid is enhanced by the presence of a kosmotropic agent. Optionally, binding of the nucleic acid to the solid phase is carried out in the presence of a kosmotropic agent. Such agents are known to enhance binding of nucleic acid to solid phases such as silica-based solid phases.

[0321] The terms “chaotropic” and “kosmotropic” agent originate from the Hofmeister series (Cacace et al., Q Rev Biophys 1997;30:241-77), which divides these agents depending on their influence on the structure of macromolecules and water. A chaotrope may be defined as a substance that breaks solvent structure, and a kosmotrope as a substance that enhances solvent structure. Figure 1 of Cacace et al shows the Hofmeister series and commonly occurring organic solutes with effects on protein structure / function. Examples of chaotropic agents are known to those in the art, and include sodium iodide, sodium perchlorate, guanidinium thiocyanate and guanidinium hydrochloride. Examples of kosmotropic agents are known to those in the art and include ammonium sulphate and lithium chloride.P107173W001

[0322] 35

[0323] Optionally, lysis is carried out using the binding buffer. Binding buffers that may be used for cell lysis are known to those of ordinary skill in the art. The lysis buffer used by Boom et al. comprises guanidinium thiocyanate, Tris hydrochloride, pH 6.4, EDTA (adjusted to pH 8), and Triton X-100. Optionally, the lysis buffer does not include a chaotropic agent. For example, a lysis / binding buffer that comprises a kosmotropic agent may be used. Optionally, the buffer is an acidic buffer, suitably a strong acidic buffer with a pKa (250C) in the range 3-5.

[0324] Kits

[0325] According to the invention there is also provided a kit for determining presence or absence in a sample of one or more of SARS-CoV-2, Influenza A, Influenza B and RSV nucleic acid, comprising a pair of oligonucleotide primers, or a set of oligonucleotides according to the invention.

[0326] Optionally, the pair of primers are for real-time PCR amplification of target nucleic acid.

[0327] Optionally, the detector probe comprises a fluorescent label. Optionally, the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0328] Optionally, the first and second primer, and the detector probe, comprise respective nucleic acid sequences according to one or more combinations of the first and second primer, and the detector probe, shown in the table below, or nucleic acid sequences which have at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along their entire length with such sequences:

[0329] Combination First primer Second primer Detector probe 1 SEQ ID NO:1 SEQ ID NO:2 SEQ ID NO:3 2 SEQ ID NO:4 SEQ ID NO:5 SEQ ID NO:6 3 SEQ ID NO:7 SEQ ID NO:8 SEQ ID NO:9 4 SEQ ID NO:10 SEQ ID NO:11 SEQ ID NO:12 5 SEQ ID NO:13 SEQ ID NO:14 SEQ ID NO:15 6 SEQ ID NO:16 SEQ ID NO:17 SEQ ID NO:18 7 SEQ ID NO:19 SEQ ID NO:20 SEQ ID NO:21 and / or

[0330]

[0331] SEQ ID NO:22

[0332] Optionally, the kit comprises one or more sets of oligonucleotides according to the invention.

[0333] Optionally, the kit comprises:P107173W001

[0334] 36

[0335] a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof;

[0336] a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: SEQ ID NO:2, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof;

[0337] a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: SEQ ID NO:4; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof;

[0338] a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:5, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof;

[0339] a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and

[0340] a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0341] Optionally, the kit comprises:

[0342] a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:1 , or the complement thereof;

[0343] a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:2, or the complement thereof;

[0344] a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: SEQ ID NO:4; or the complement thereof;P107173W001

[0345] 37

[0346] a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:5, or the complement thereof;

[0347] a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and

[0348] a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0349] Optionally, the kit according to the invention further comprises an RNA-dependent DNA polymerase for reverse transcription of SARS-CoV-2 RNA, Influenza A RNA, Influenza B RNA and RSV RNA and a DNA-dependent DNA polymerase for real-time PCR (rt-PCR) amplification and detection of reverse-transcribed SARS-CoV-2 RNA, Influenza A RNA, Influenza B RNA and RSV RNA using the, or each, pair of oligonucleotide primers and the detector probe, or a set of oligonucleotides.

[0350] Optionally, the kit further comprises dNTPs and / or reaction buffer for reverse transcription and rt-PCR amplification.

[0351] Optionally, the kit comprises a swab stick for obtaining a nasopharyngeal or a throat swab sample from a subject.

[0352] Optionally, the kit according to the invention further comprises a lysis / binding buffer, an elution buffer, and optionally, a wash buffer, for extracting nucleic acid from a biological sample obtained from a subject.

[0353] There is also provided according to the invention use of an oligonucleotide according to the invention, a pair of oligonucleotide primers according to the invention, or a set of oligonucleotides according to the invention, or a kit according to the invention, for determining whether a sample includes one or more of SARS-CoV-2 nucleic acid, and / or Influenza A nucleic acid, and / or Influenza B nucleic acid, and / or RSV nucleic acid.

[0354] Optionally, the use of the oligonucleotide, pair of oligonucleotide primers, set of oligonucleotides, or kit, according to the invention, is in a method according to the invention.

[0355] Internal control

[0356] An internal process control may be used in the method of the present invention to monitor for correct function of the test, from extraction to amplification and detection. Optionally, the internal control is bacteriophage MS2.P107173W001

[0357] 38

[0358] Optionally, the MS2 internal control nucleic acid is amplified and detected with a set of oligonucleotide primers and probes comprising the following nucleic acid sequences, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of any one of these nucleic acid sequences, or the complement thereof.

[0359] Primer MS2_F: GAC AAT GGC GGA ACT GGC (SEQ ID NO: 23)

[0360] Primer MS2_R: CGA GTT AGA GOT GAT CCA TTC AG (SEQ ID NO: 24)

[0361] Probe MS2: CGC CCC AAG CAA CTT CGC TAA (SEQ ID NO: 25)

[0362] Labels

[0363] Any suitable label may be used in methods or with oligonucleotides (or sets of oligonucleotides) of the invention. Examples include fluorescent labels.

[0364] ATTO fluorescent dyes are a family of synthetic organic molecules that are widely used as fluorescent labels for biological imaging and analysis. They are developed by ATTO-Tec GmbH, in Germany, and are known for their high photostability and brightness compared to other fluorescent dyes of the same wavelength. ATTO dyes are particularly notable for their superior performance and versatility.

[0365] ATTO dyes are characterised by high fluorescence, quantum yields, strong absorption and increased thermal and photo-stability. These beneficial properties are due to their unique molecular structure. Unlike most common dyes, such as cyanines, which have a flexible structure, ATTO dyes feature a highly rigid chromophore. Most ATTO-labels are derivatives of coumarin, acridine, rhodamine, carbopyronin and oxazine:P107173W001

[0366] 39

[0367] o

[0368]

[0369] Coumarin Acridine

[0370] Carbopyronin

[0371] Rhodamine

[0372]

[0373] Oxazine

[0374] This rigid structure prevents the formation of isomers in solution, ensuring consistent optical properties. While many other dyes are prone to variations in their optical properties, ATTO dyes perform nearly independently of solvent and temperature. Many ATTO dyes also have additional properties, such as a large Stokes-shift, high ozone resistance and good water solubility.

[0375] ATTO dyes cover a broad spectral range - from 350 nm in the UV range to 750 nm in the near infrared - and include dyes compatible with the most frequently used excitation sources. Their broad excitation signal maxima range and good Stokes-shift separation make them suitable for most techniques, while also enabling multiplexing. Stokes-shift is the difference between the absorption and emission peak for fluorophores. A larger Stokes-shift reduces self-quenching and improves the signal-to-noise ratio. This also minimises the inner filter effect and is advantageous in multicolour imaging.

[0376] Advantages of ATTO dyes include:

[0377] Reduced background / noise: Many ATTO dyes can be stimulated by wavelengths beyond 600 nm. The use of these long wavelengths activated ATTO dyes with the right excitation wavelength can decrease autofluorescence, as well as background fluorescence fromP107173W001

[0378] 40

[0379] Rayleigh and Raman scattering, thereby enhancing sensitivity in biological analysis and imaging techniques.

[0380] High photostability: ATTO-labels are designed with improved stability, even under prolonged irradiation. ATTO 655 and ATTO 647N are also resistant to ozone degradation. Moreover, most dyes’ hydrophilic nature makes them highly suitable for labelling in aqueous solutions.

[0381] Improved signal detection: ATTO dyes have longer fluorescence signal lifetimes ranging from 0.6 to 4.1 ns, compared to carbocyanine dyes and many inherent auto fluorescent biomolecules. This allows clear and more accurate signal measurement using pulsed laser excitation with a time-gated detection system, resulting in decreased interference from fluorophores with shorter lifetimes, background autofluorescence, as well as Rayleigh and Raman light scattering.

[0382] Multiplexing ability: ATTO dyes are well-suited for multiplex techniques using visible and near infrared emission wavelengths because of their strong fluorescent signals, with most of them having molar absorptivity values over 100,000. Additionally, their low excitation / emission overlap further enhances their suitability for multiplexing.

[0383] Examples of suitable ATTO dyes for use according to the invention are provided in the table below:

[0384] Dye Position Specs Features Applications Quenchers ATTO 390 5', 3' Coumarin • Fluoresces in the Can be used in BHQ™-1

[0385] derivative blue region of the a wide array of

[0386] visible spectrum

[0387] • Large Stokes- applications.

[0388] shift

[0389] • Moderately

[0390] hydrophilic

[0391] • Low molecular

[0392] weight

[0393] ATTO 425 5', 3' Coumarin • Fluoresces in the Dual-labelled BHQ-0

[0394] derivative blue region of the fluorogenic

[0395] visible spectrum

[0396] • Large Stokes- probes for realshift time PCR.

[0397] Moderately hydrophilic

[0398] ATTO 465 5', internal, 3' Derived from • Fluoresces in the Dual-labelled BHQ-1

[0399] acriflavine green region of fluorogenic

[0400] the visible

[0401] Cationic dye spectrum probes for real• Large Stokes- time PCR.

[0402] shift in aqueous

[0403] solution

[0404] • High triplet yield,

[0405]

[0406] intenseP107173W001

[0407] 41

[0408] phosphorescence

[0409] in solid matrix

[0410] • Hydrophilic

[0411] ATTO 488 5', 3' Rhodamine • Fluoresces in the Single BHQ-1 derivative green region of molecule

[0412] the visible

[0413] spectrum detection, high- • High photoresolution

[0414] stability

[0415] microscopy,

[0416] • Very hydrophilic

[0417] • Excellent water and FISH.

[0418] solubility

[0419] ATTO 5', 3' • Exhibits an Ideal for BHQ-2 490LS extremely large applications stokes shift of

[0420] 165 nm that require

[0421] • Fluoresces in the multiplexing.

[0422] far-red region of

[0423] the visible

[0424] spectrum

[0425] • Very hydrophilic

[0426] with excellent

[0427] water solubility

[0428] ATTO 514 3' Rhodamine • Fluoresces in the Single BHQ-1 derivative green region of molecule

[0429] the visible

[0430] spectrum detection, high- • High thermal and resolution

[0431] photo-stability

[0432] microscopy,

[0433] • Very hydrophilic

[0434] • Excellent water and FISH.

[0435] solubility

[0436] ATTO 520 5', 3' Rhodamine • Fluoresces in the Dual-labelled BHQ-1 derivative green region of fluorogenic

[0437] the visible

[0438] spectrum probes for real• High thermal and time PCR.

[0439] photo-stability

[0440] • Hydrophobic

[0441] • At pH>7

[0442] reversible

[0443] formation of

[0444] colourless

[0445] pseudobase

[0446] ATTO 532 5', internal, 3' Rhodamine • Fluoresces in the Single BHQ-1 derivative green region of molecule

[0447] the visible

[0448] spectrum detection, high- • High photoresolution

[0449] stability

[0450] microscopy,

[0451] • Very hydrophilic

[0452] • Excellent water and FISH.

[0453] solubility

[0454] ATTO 550 5', 3' Rhodamine • Fluoresces in the Single BHQ-2 derivative yellow region of molecule

[0455] the visible

[0456] Cationic dye spectrum detection, high- resolution

[0457]

[0458] P107173W001

[0459] 42

[0460] • High thermal and microscopy, photo-stability and FISH.

[0461] • Moderately

[0462] hydrophilic

[0463] ATTO 565 5', 3' Rhodamine • Fluoresces in the Single BHQ-2 derivative orange region of molecule

[0464] the visible

[0465] spectrum detection, high- • High thermal- resolution

[0466] and photostability microscopy,

[0467] • Moderately and FISH.

[0468] hydrophilic

[0469] ATTO 5' Rhodamine • Fluoresces in the Dual-labelled BHQ-2 rho12 derivative red region of the fluorogenic

[0470] visible spectrum

[0471] • High thermal and probes for realphoto-stability time PCR

[0472] • Moderately

[0473] hydrophilic

[0474] ATTO Rhodamine Dual-labelled BHQ-2

[0475] 5’, 3’ • Fluoresces in the

[0476] rho101 derivative red region of the fluorogenic

[0477] visible spectrum

[0478] • High thermal and probes for realphoto-stability time PCR.

[0479] • Moderately

[0480] hydrophilic

[0481] ATTO 590 Rhodamine Single BHQ-2

[0482] 5', internal, 3' • Fluoresces in the

[0483] derivative orange region of molecule

[0484] the visible

[0485] spectrum detection, high- • High thermal and resolution

[0486] photo-stability

[0487] microscopy,

[0488] • Moderately

[0489] hydrophilic and FISH.

[0490] ATTO 594 Rhodamine Single BHQ-2

[0491] 5’, 3’ • Fluoresces in the

[0492] derivative red region of the molecule

[0493] visible spectrum

[0494] • High photodetection, high- stability resolution

[0495] • Very hydrophilic microscopy,

[0496] • Excellent water

[0497] solubility and FISH.

[0498] ATTO 620 Rhodamine Dual-labelled BHQ-2

[0499] 5’, 3’ • Fluoresces in the

[0500] derivative red region of the fluorogenic

[0501] visible spectrum

[0502] • Fluorescence probes for realyield strongly time PCR. dependent on

[0503] temperature

[0504] • High thermal and

[0505] photo-stability

[0506] • Moderately

[0507] hydrophilic

[0508]

[0509] P107173W001

[0510] 43

[0511] ATTO 633 Carborhodamine Single BHQ-3

[0512] 5', internal, 3' • Fluoresces in the

[0513] dyes red region of the molecule

[0514] visible spectrum

[0515] Cationic • High thermal and detection, high- photo-stability resolution

[0516] • Moderately microscopy,

[0517] hydrophilic

[0518] and FISH.

[0519] ATTO 647 N Carborhodamine Single BHQ-2

[0520] 5', internal, 3' • Fluoresces in the

[0521] dyes red region of the molecule

[0522] visible spectrum

[0523] Cationic • Extraordinary detection, high- high fluorescence resolution

[0524] yield

[0525] microscopy

[0526] • High thermal and

[0527] photo-stability and FISH.

[0528] • Excellent ozone

[0529] resistance

[0530] • Moderately

[0531] hydrophilic

[0532] ATTO 655 Oxazine Single BHQ-3

[0533] 5’, 3’ • Fluoresces in the

[0534] derivative red region of the molecule

[0535] visible spectrum

[0536] Zwiterionic dye • Excellent thermal detection, high- and photoresolution

[0537] stability

[0538] microscopy

[0539] • Excellent ozone

[0540] resistance and FISH.

[0541] • Hydrophilic

[0542] ATTO 680 Oxazine Dual-labelled BHQ-3 dye 5', internal, 3' • Fluoresces in the

[0543] derivative red region of the fluorogenic Fluorescence visible spectrum

[0544] Zwiterionic dye • Excellent probes for realquenching by thermal- and time PCR. electron photo-stability

[0545] donors like • Hydrophilic

[0546] guanine, tryptophan, etc.

[0547] ATTO 700 Single BHQ-3 dye 5’, 3’ Oxazine • Fluoresces in the

[0548] red region of the molecule Fluorescence derivative visible spectrum

[0549] • Excellent detection, high- quenching by Zwitterionic dye thermal- and resolution electron photo-stability

[0550] microscopy, donors like • Hydrophilic

[0551] and FISH. guanine, tryptophan, etc.

[0552] ATTO 725

[0553] 5’ • Fluoresces in the

[0554] near infrared Can be used in

[0555] region of the a wide array of

[0556] spectrum

[0557] • Strong absorption applications.

[0558] • Excellent thermal

[0559] and photostability

[0560] • Stable up to pH

[0561] 7.4

[0562]

[0563] P107173W001

[0564] 44

[0565] ATTO 740

[0566] 5’, 3’ • Fluoresces in the

[0567] near infrared Can be used in

[0568] region of the a wide array of

[0569] spectrum

[0570] • Excellent photoapplications.

[0571] stability

[0572] • Moderately

[0573] hydrophilic

[0574] • Stable at pH 2-8

[0575]

[0576] For example, ATTO 488 is a fluorescent label with excellent water solubility. Characteristic features of the label are strong absorption, high fluorescence quantum yield, high photostability, and very little triplet formation. Thus ATTO 488 is highly suitable for single-molecule detection applications and high-resolution microscopy such as PALM, dSTORM, STED etc. Additionally, the dye highly qualifies to be applied in flow cytometry (FACS), fluorescence in-situ hybridization (FISH) and many more. The fluorescence is excited most efficiently in the range 480 - 515 nm. For instance, the 488 nm line of the Argon-lon laser is very suitable for excitation.

[0577] Atto 647N is a superior red-emitting fluorescence dye with a strong absorption, excellent fluorescence quantum yield (65%), high photostability, excellent ozone resistance, good solubility, and very little triplet formation. ATTO 647N belongs to a new generation of fluorescent labels for the red spectral region. The dye is designed for application in life science, e.g. labelling of DNA, RNA or proteins. Characteristic features of the label are strong absorption, excellent fluorescence quantum yield, high photostability, excellent ozone resistance, good solubility, and very little triplet formation. Atto 647N is a cationic dye. The active ester of Atto 647N fluorescence dye reacts with amino groups under mild conditions. After coupling to a substrate, the dye carries a net electrical charge of +1. In common with most Atto-labels, absorption and fluorescence are independent of pH in the range of 2 to 11 , used in typical applications. As supplied Atto 647N consists of a mixture of two isomers with practically identical absorption and fluorescence properties. The fluorescence is excited most efficiently in the range 625 - 660 nm. A suitable excitation source is the 647 nm line of the Krypton-lon laser or a diode-laser emitting at 650 nm.

[0578] ATTO 700 is a label with high molecular absorption (1.2 x 105) and quantum yield (0.25) as well as sufficient Stoke's shift between excitation and emission maximum. Atto 700 is characterized by high photostability and thermal stability. It is also excellently soluble in water. Due to an insignificant triplet formation rate, it is well suited for single molecule detection applications. Atto 700 belongs to a new generation of fluorescent labels. The dye is designed for application in labeling of DNA, RNA or proteins. Characteristic features of the label are strong absorption, high fluorescence quantum yield, excellent thermal and photo-P107173W001

[0579] 45

[0580] stability, very good water solubility and very little triplet formation. Atto 700 is a zwitterionic dye with a net electrical charge of zero. The fluorescence is efficiently quenched by electron donors like guanine, tryptophan, etc. Atto labels have rigid structures that do not show any c / s-frans-isomerization. Thus, these labels display exceptional intensity with minimal spectral shift on conjugation.

[0581] ATTO 532 is a fluorescent label related to the well-known dye Rhodamine 6G. Characteristic features of the label are strong absorption, high fluorescence quantum yield, high photostability, and excellent water solubility. Thus ATTO 532 is highly suitable for single-molecule detection applications and high-resolution microscopy such as SIM, STED etc. Additionally, the dye highly qualifies to be applied in flow cytometry (FACS), fluorescence in-situ hybridization (FISH) and many more. The fluorescence is excited most efficiently in the range 515 - 545 nm. A suitable excitation source for ATTO 532 is the 532 nm output of the frequency-doubled Nd:YAG laser.

[0582] ATTO Rho101 is a derivative of the well-known dye Rhodamine 101. Characteristic features of the label are strong absorption, extraordinarily high fluorescence quantum yield, and high thermal and photo-stability. The dye is moderately hydrophilic. ATTO Rho101 is a cationic dye. After coupling to a substrate, the dye carries a net electrical charge of +1. Its fluorescence can be excited efficiently in the range 570 - 600 nm.

[0583] ATTO 490LS is a new fluorescent label featuring an extraordinarily large Stokes-shift of 165 nm. Thus, the emission spectrum is almost completely separated from the absorption spectrum, making the dye highly suitable for multicolor experiments, in particular in combination with ATTO 488 and ATTO 514. ATTO 490LS is very hydrophilic, highly water soluble, and exhibits a relatively high fluorescence quantum yield, which is only slightly reduced on conjugation to biomolecules, e.g. proteins, even at high degrees of labeling (DOL). ATTO 490LS is an anionic dye. After conjugation to a substrate the dye carries a net electrical charge of -1. The fluorescence is excited most efficiently in the range 460 - 530 nm.

[0584] Quenchers

[0585] Quenchers are a class of molecules with the capability to suppress fluorescence emission intensity via a mechanism known as fluorescence resonance energy transfer (FRET). This process requires the emission spectrum of the reporter dye (donor) to have sufficient spectral overlap with the absorbance spectrum quencher dye (acceptor). FRET also requires the two molecules to be in the correct relative orientation within close spatial proximity to one another. When these conditions are met, transfer of energy from an excited reporter dye to the quencher returns the reporter dye to its ground state without any light emission or absorptionP107173W001

[0586] 46

[0587] between the two dyes. Simultaneously, via a dipole coupling, the absorbed energy of the acceptor raises the quencher to an excited state. The quencher will then dissipate this energy proportional to the transferred energy from the donor dye.

[0588] Black Hole Quencher™ (BHQ™) dyes are numbered according to the range of the visible spectrum in which they are most effective, from zero to three. BHQ dyes are members of a special class of quencher dyes known as “Dark Quenchers”. These dyes have broad absorption ranges in the visible spectrum, but have no native fluorescence themselves, in contrast to non-dark quenchers like tetramethylrhodamine (TAMRA), which can contribute to background signal in an assay. BHQ dyes suppress signal from a wide range of fluorophores without potentially contributing to background fluorescence, enabling highly multiplexed nucleic acid assays.

[0589] The FRET quenching mechanism relies on spatial proximity and overlap of the spectral characteristics of the reporter’s emission and the quencher’s absorbance. When in proximity, typically within 10 nanometers distance to one another, there is an electronic interaction in which a transfer of energy from the reporter dye to the quencher results in the transferred energy dissipating via the quencher. If the quencher is a dark quencher such as BHQ, the energy does not cause photon emission but rather is partially released in the form of heat from the quencher as it relaxes to its ground state. To put more simply, BHQ quenching via the FRET mechanism takes the excited reporter dye’s energy and transforms it so that the reporter dye returns to a ground state while suppressing any release of light.

[0590] Static quenching

[0591] While BHQ dyes participate in the more well-known FRET Quenching mechanism, they can also efficiently operate via Static (contact) quenching mechanisms, elucidated in a series of studies from 2002. The second mechanism of quenching is referred to as contact quenching, also known as static quenching. Through this mechanism, the fluorophore and quencher physically interact to form an intramolecular dimer. This dimerization of the two chromophores essentially creates a new, non-fluorescent compound. Static quenching relies on the affinity of the dye and the quencher for one another. Because BHQ dyes and many fluorophores are planar hydrophobic molecules, they will often strongly associate in aqueous solutions, thus assisting in creating these intramolecular dimers. In the case of either quenching mechanism, there is a requirement to achieve a high local concentration of both the fluorophore and quencher. As such, quenching mechanisms are typically not effective as free chromophore monomers, but rather the reporter dye and quencher must be closely tethered to each other by linking them to the same molecule, as is the case in a Dual-LabeledP107173W001

[0592] 47

[0593] BHQ probe. Black Hole Quencher dyes have the capacity to operate through both mechanisms of quenching, allowing BHQ-conjugated oligos to effectively snuff out the signal from reporter dyes.

[0594] Selecting the appropriate non-fluorescent quencher

[0595] One important consideration in choosing the correct BHQ dye is to ensure that a quencher is selected with an absorption range best matched to the fluorescent reporter.

[0596] Black Hole Quencher modifications for custom oligonucleotides

[0597] Dye Effective quenching 5’ Mod. 3’ Mod. Internal range mod.

[0598] BHQ-0 430-520 nm

[0599] BHQ-1 480-580 nm J J J

[0600] T(BHQ-1) 480-580 nm

[0601] BHQ-2 559-670 nm

[0602] T(BHQ-2) 559-670 nm y

[0603] BHQ-3 620-730 nm y y

[0604]

[0605]

[0606]

[0607] BHQ modifications to oligos can be used in several common probe formats for molecular assays, including qPCR, such as Dual-Labeled BHQ probes and BHQplus® probes. All BHQ dyes are available as terminal 5’ and 3’ modifications to an oligonucleotide. Many of them are also available as internal BHQ modifications, which come in two versions. Standard internal BHQ modifications incorporate an abasic linkage through the sugar-phosphate backbone of the oligo. This version of the internal BHQ may impact oligonucleotide geometry upon hybridization since it sits between the standard base linkages on either side of the modification. There is also a version of the internal modification, T(BHQ), where the quencher is attached to a deoxythymidine (dT) nucleoside to allow continuity of the oligonucleotide backbone. This minimizes the potential disruption of hybridization by linking the quencher off the base. The structure of the BHQ-1 abasic and T-linked modifications are shown side by side here as point of comparison.P107173W001

[0608] 48

[0609] Internal BHQ-1 Modification / / [BHQ-1]

[0610]

[0611] Internal Thymidine linked BHQ-1 Modification / / [T(BHQ-1)]

[0612]

[0613] The number of available Black Hole Quencher dyes and modification arrangements presents a large degree of customization options for oligos. Static and FRET quenching mechanisms of the BHQ line of dyes provides effective quenching across the visible spectrum.

[0614] The method of the invention has high sensitivity and high specificity. Typically, the method is highly sensitive in detecting any virus described herein and will detect very low amounts of virus. Typically, the method is highly specific in detecting any virus described herein, and for example will not detect any other virus.

[0615] DRAWINGS

[0616] Embodiments of the invention are described below, by way of example only, with reference to the accompanying drawings in which:

[0617] Figure 1 shows the genome organisation of SARS-CoV-2 (isolate Wuhan-Hu-1, GenBank Acc MN 908947);

[0618] Figures 2 A-C show the genome organisation of Influenza A virus, Influenza B virus and RSV, respectively;

[0619] Figure 3 shows schematically the steps for reverse transcription real-time PCR amplification of a target RNA;

[0620] Figure 4a shows detection of target nucleic acid using a fluorescent hydrolysis probe, and Figure 4b shows the detection of target nucleic acid using fluorescent Molecular Beacon probes.P107173W001

[0621] 49

[0622] SEQ ID Nos of primers and probes:

[0623] SEQ ID

[0624] Name Sequence

[0625] NO:

[0626] 1 Primer S3 SCoV- GAG GAC AAT CAG ACA ACT ACT ATT C

[0627] 2_ORF1ab_F1

[0628] 2 Primer S3 SCoV- AGT CTG AAC AAC TGG TGT AAG T

[0629] 2_ORF1ab_R1

[0630] 3 Probe S3 SCoV- TGA GGT TCA ACC TCA ATT AGA GAT GG

[0631] 2_ORF1ab_1

[0632] 4 Primer S3 SCoV-2_ORF8_F2 GAA TTG TGC GTG GAT GAG

[0633] 5 Primer S3 SCoV- TAC AAG ACT ACC CAA TTT AGG TTC

[0634] 2_ORF8_R2

[0635] 6 Probe S3 SCoV-2_ORF8_2 CTG GTT CTA AAT CAC CCA TTC AGT 7 Primer S3 FluA_MP2_F2 CAT TTT GGA CAA AGC GTC TA

[0636] 8 Primer S3 FluA _MP2_R2 ACC RAT CCT GTC ACC TYT GAC

[0637] 9 Probe S3 FluA_MP2_2 CCG TGC CCA GTG AGC G

[0638] 10 Primer S3 FluA_PB2_F1 ACT AAT TGA TGG CCA TYC GAA T 11 Primer S3 FluA_PB2_R1 TGA AAC GRA AAC GGG ACT CTA G 12 Probe S3 FluA_PB2_1 ACA GCC AGA CAG CGA CCA A

[0639] 13 Primer S3 FluB_NEP_F1 CTC GAA GAG TGA RTT GAG GAT 14 Primer S3 FluB_NEP_R1 TGG AAG GCT TGT TGC TAA

[0640] 15 Probe S3 FluB_NEP_1 TAC AGT GGA GGA TGA AGA AGA TGG 16 Primer S3 FluB_PB2_F2 GCA TTT CCT TGG TGA GAG AG

[0641] 17 Primer S3 FluB_PB2_R2 AGA CTT GAC AAY GCC ACT T

[0642] 18 Probe S3 FluB_PB2_2 ACT TTT GGC CCA GTT GAA AG

[0643] 19 Primer S3 RSV_P_F GGA TTG AGA GAC ACT TCA TCT G 20 Primer S3 RSV_P_R GGT TGG TYT AAG AGA AGA AAT GA 21 Probe S3 RSV_P_1 AGC TAT GGC AAG ACT CAG GAA TG 22 Probe S3 RSV_P_2 CTA TGG CAA GAC TTA GGA ATG AGG 23 Primer MS2_F GAC AAT GGC GGA ACT GGC

[0644] 24 Primer MS2_R CGA GTT AGA GCT GAT CCA TTC AG 25

[0645]

[0646] Probe MS2 CGC CCC AAG CAA CTT CGC TAAP107173WQ01

[0647] 50

[0648] EXAMPLES

[0649] Design of primers and probes for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

[0650] Two sets of primers and probes were designed to amplify and detect SARS-CoV-2. Each set comprises a forward and a reverse primer and a detector probe. The designed sequences are shown below:

[0651] Set 1

[0652] Forward

[0653] Primer S3 SCoV-2_ORF1 ab_F1 : GAG GAC AAT CAG ACA ACT ACT ATT C (SEQ ID NO: 1)

[0654] Reverse

[0655] Primer S3 SCoV-2_ORF1ab_R1 : AGT CTG AAC AAC TGG TGT AAG T (SEQ ID NO:2)

[0656] Detector

[0657] Probe S3 SCoV-2_ORF1 ab_1 : TGA GGT TCA ACC TCA ATT AGA GAT GG (SEQ ID NO:3) Set 2

[0658] Forward primer

[0659] Primer S3 SCoV-2_ORF8_F2: GAA TTG TGC GTG GAT GAG (SEQ ID NO:4)

[0660] Reverse primers

[0661] Primer S3 SCoV-2_ORF8_R2: TAC AAG ACT ACC CAA TTT AGG TTC (SEQ ID NO:5) Detector probe

[0662] Probe S3 SCoV-2_ORF8_2: CTG GTT CTA AAT CAC CCA TTC AGT (SEQ ID NO:6) Design of primers and probes for detection of Influenza A

[0663] Two sets of primers and probes were designed to amplify and detect Influenza A. Each set comprises a forward and a reverse primer and a detector probe. The designed sequences are shown below:

[0664] Set 3

[0665] Forward primer

[0666] Primer S3 FluA_MP2_F2: CAT TTT GGA CAA AGC GTC TA (SEQ ID NOT)

[0667] Reverse primers

[0668] Primer S3 FluA_MP2_R2: ACC RAT CCT GTC ACC TYT GAC (SEQ ID NO:8)P107173WQ01

[0669] 51

[0670] Detector probe

[0671] Probe S3 FluA_MP2_2: CCG TGC CCA GTG AGC G (SEQ ID NO:9)

[0672] Set 4

[0673] Forward primer

[0674] Primer S3 FluA_PB2_F1 : ACT AAT TGA TGG CCA TYC GAA T (SEQ ID NO: 10) Reverse primers

[0675] Primer S3 FluA_PB2_R1 : TGA AAC GRA AAC GGG ACT CTA G (SEQ ID NO: 11) Detector probe

[0676] Probe S3 FluA_PB2_1 : ACA GCC AGA CAG CGA CCA A (SEQ ID NO:12)

[0677] Design of primers and probes for detection of Influenza B

[0678] Two sets of primers and probes were designed to amplify and detect Influenza B. Each set comprises a forward and a reverse primer and a detector probe. The designed sequences are shown below:

[0679] Set 5

[0680] Forward primer

[0681] Primer S3 FluB_NEP_F1 : CTC GAA GAG TGA RTT GAG GAT (SEQ ID NO: 13)

[0682] Reverse primers

[0683] Primer S3 FluB_NEP_R1: TGG AAG GCT TGT TGC TAA (SEQ ID NO:14)

[0684] Detector probe

[0685] Probe S3 FluB_NEP_1 : TAC AGT GGA GGA TGA AGA AGA TGG (SEQ ID NO:15)

[0686] Set 6

[0687] Forward primer

[0688] Primer S3 FluB_PB2_F2: GCA TTT CCT TGG TGA GAG AG (SEQ ID NO:16)

[0689] Reverse primers

[0690] Primer S3 FluB_PB2_R2: AGA CTT GAC AAY GCC ACT T (SEQ ID NO:17)

[0691] Detector probe

[0692] Probe S3 FluB_PB2_2: ACT TTT GGC CCA GTT GAA AG (SEQ ID NO:18)

[0693] Design of primers and probes for detection of RSV

[0694] One set of primers and probes were designed to amplify and detect RSV. The set comprises a forward and a reverse primer and two detector probes for detection of RSV type A and type B. The designed sequences are shown below:P107173WQ01

[0695] 52

[0696] Set 7

[0697] Forward primers

[0698] Primer S3 RSV_P_F: GGA TTG AGA GAC ACT TCA TCT G (SEQ ID NO: 19) Reverse primers

[0699] Primer S3 RSV_P_R: GGT TGG TYT AAG AGA AGA AAT GA (SEQ ID NO:20) Detector probe

[0700] Probe S3 RSV_P_1 : AGC TAT GGC AAG ACT CAG GAA TG (SEQ ID NO:21) Probe S3 RSV_P_2: CTA TGG CAA GAC TTA GGA ATG AGG (SEQ ID NO:22)

[0701] Example 2

[0702] Limit of detection

[0703] The Limit of detection (LoD) of the SCoV-2 / Influenza A I Influenza B / RSV multiplex test according to the method of the invention on combined nasal and throat swab specimens using specimens spiked with different concentrations of SARS CoV-2, Influenza A (H1N1 or H3N2), Influenza B or RSV (A or B) using the sets of primers and probes of Example 1 was estimated by Probit analysis.

[0704] SARS-CoV-2

[0705] Using the First WHO International Standard for SARS CoV-2 RNA (NIBSC Code 20 / 146), five (5) concentrations (350, 250, 150, 100 and 50 I U / ml) diluted in pooled negative combined nose and throat swab specimens in specimen buffer were tested in 24 replicates per concentration. The LoD was confirmed at 174 lU / ml (95% Cl : 115-194) as shown in Table 1.

[0706] Influenza A H1N1

[0707] For Influenza A H1N1, the LoD was determined by testing five (5) concentrations (100, 75, 50, 35 and 25 U / mL) diluted in pooled negative combined nose and throat swab specimens collected in specimen buffer in 24 replicates per concentration. The final LOD was confirmed at 41 U / ml (95% Cl: NA-44) as shown in Table 1.

[0708] Influenza A H3N2

[0709] For Influenza A H3N2, the LoD was determined by testing five (5) concentrations (125, 100, 75, 50 and 25 U / mL) diluted in pooled negative combined nose and throat swab specimens collected in specimen buffer in 24 replicates per concentration. The final LOD was confirmed at 74 U / ml (95% CI:46-83) as shown in Table 1.P107173W001

[0710] 53

[0711] Influenza B

[0712] For Influenza B, the LoD was determined by testing five (5) concentrations (350, 250, 150, 100 and 50 U / rnL) diluted in pooled negative combined nose and throat swab specimens in specimen buffer in 24 replicates per concentration. The final LoD was confirmed at 153 U / rnL (95% Cl 89-176) as shown in Table 1.

[0713] Respiratory Syncytial Virus (RSV) A

[0714] For Respiratory Syncytial Virus (RSV) A, the LoD was determined by testing six (6) concentrations (300, 250, 200, 150, 100 and 50 U / mL) diluted in pooled negative combined nose and throat swab specimens in specimen buffer in at least 24 replicates per concentration. The final LoD was estimated at 138 U / mL (95% Cl: 40-228) as shown in Table 1.

[0715] Respiratory Syncytial Virus (RSV) B

[0716] For Respiratory Syncytial Virus (RSV) B, the LoD was determined by testing five (5) concentrations (250, 200, 150, 100 and 50 U / mL) diluted in pooled negative combined nose and throat swab specimens in specimen buffer in at least 24 replicates per concentration. The final LoD was estimated at 144 U / mL (95% Cl: 105-161) as shown in Table 1.

[0717] Table 1 : LoD of the SCoV-2 / Influenza A / Influenza B / RSV Multiplex Test

[0718] Microorganism Virus source and strain LoD 95% Cl SARS-CoV-2 First WHO International Standard for SARS-CoV-2 174 I U / ml 115-194

[0719] RNA (NIBSC code 20 / 146)

[0720] Influenza A (H1N1) NIBSC Working Standard Winter Respiratory Panel for 41 U / ml NA-44

[0721] Influenza A H1N1 (20-180)

[0722] Influenza A (H3N2) NIBSC Working Standard Winter Respiratory Panel for 74 U / ml 46 - 83

[0723] Influenza A H3N2 (2G0-182)

[0724] Influenza B NIBSC Working Standard Winter Respiratory Panel for 153 U / ml 89 - 176

[0725] Influenza B (20-184)

[0726] RSV A NIBSC Working Standard Winter Respiratory Panel for 138 U / ml 40-228

[0727] RSV-A (20-186)

[0728] RSV B NIBSC Working Standard Winter Respiratory Panel for 144 U / ml 105-161

[0729]

[0730] RSV-B (20-188)P107173W001

[0731] 54

[0732] Example 3

[0733] Bench testing

[0734] The SCoV-2 / Influenza A I Influenza B / RSV multiplex test was assessed by testing a panel of bacterial and fungal strains as well as other viruses which cause similar symptoms as SARS CoV-2, Influenza and RSV or those that are commonly associated with respiratory tract infections and normal nasal / throat microflora. Additionally, potential interference from these microorganisms against test target detection was assessed by spiking high concentration of the background strain(s)and low level (3X LOD) of the test target organisms (SARS-CoV-2, Influenza A, Influenza B and RSV).

[0735] Bench testing with available representative strains of microorganisms, including those that showed >80% homology with in silico analysis, at 105-106cells / ml for bacteria / fungi and 102- 105pfu or TCID50 / ml for viruses (Table 2) in specimen buffer showed that SARS-CoV-2, Influenza A, Influenza B and / or RSV at low levels were detected by the SCoV-2 / Influenza A / Influenza B / RSV multiplex test of the invention in spiked samples. The non spiked negative samples gave negative results indicating that the assay is specific and confirmed the results from in silico analysis.

[0736] Table 2. Specific strains used in wet testing for cross-reactivity.

[0737] Microorganism Source Accession Final number concentration tested Acinetobacter calcoaceticus ATCC 23055 105 / ml Arcanobacterium haemolyticum ATCC 9345 105 / ml Burkholderia orbicola (formerly B. cepacia)

[0738] ATCC 17762 105 / ml Chlamydia trachomatis ZeptoMetrix 801775 105 / ml Corynebacterium diphtheriae ZeptoMetrix 801882 105 / ml Bordetella avium ATCC 35086 105 / ml Bordetella bronchiseptica ATCC 10580 105 / ml Bordetella hinzii ATCC 51783 105 / ml Bordetella holmesii ATCC 700052 105 / ml Chlamvdophila pneumoniae TW-183 ATCC VR-2282 105 / ml Corynebacterium striatum ATCC BAA-1293 105 / ml Enterobacter cloacae AR Bank #0038 105 / ml

[0739]

[0740] P107173W001

[0741] 55

[0742] Escherichia coli AR Bank #0538 105 / ml Fusobacterium necrophorum subsp

[0743] necrophorum ATCC 27852 105 / ml Haemophilus influenzae ATCC 33391 105 / ml Haemophilus influenzae ATCC 49766 105 / ml Klebsiella pneumoniae AR Bank #0039 105 / ml Lactobacillus acidophilus ZeptoMetrix 801540 105 / ml Lactobacillus plantarum ZeptoMetrix 804436 105 / ml Legionella (Fluoribacter) bozemanae ATCC 33217 105 / ml Legionella (Fluoribacter) dumoffii ATCC 33279 105 / ml Legionella longbeachae ZeptoMetrix 801577 105 / ml Legionella (Tatlockia) micdadei ZeptoMetrix 801576 106 / ml Legionella pneumophila ZeptoMetrix 804007 106 / ml Leptospira interrogans serovar

[0744] Copenhageni strain Fiocruz L1-130 ATCC BAA-1198D-5 0.7 ug / 100 pl Moraxella catarrhalis ATCC 8176 105 / ml Mycoplasma orale ATCC 19524 105 / ml Mycoplasma hominis ZeptoMetrix 804011 105 / ml Mycoplasma pulmonis BEI NR-3858 104 / ml Mycobacterium tuberculosis, HN878, BEI NR-49100

[0745] gamma-irradiated whole cells

[0746] 105 / ml Neisseria elongata ZeptoMetrix 801510 105 / ml Neisseria gonorrhoeae ATCC 19424 105 / ml Neisseria meningitidis ATCC 13090 105 / ml Proteus mirabilis ATCC 12453 105 / ml Pseudomonas aeruginosa ATCC 27853 105 / ml Serratia marcescens AR Bank #0091 105 / ml Staphylococcus aureus subsp aureus ATCC 10832 105 / ml Staphylococcus epidermidis ATCC 29887 105 / ml Streptococcus agalactiae ATCC 13813 105 / ml Streptococcus dysgalactiae subsp

[0747] dysgalactiae ATCC 43078 105 / ml Streptococcus pneumoniae ATCC BAA-341 105 / ml Streptococcus pyogenes ATCC 19615 105 / ml Streptococcus salivarius subsp salivarius ATCC 13419 105 / ml

[0748]

[0749] P107173W001

[0750] 56

[0751] Ureaplasma urealyticum ATCC 27618 105 / ml Aspergillus flavus ZeptoMetrix 801598 105 / ml Aspergillus fumigatus ZeptoMetrix 801716 105 / ml Candida albicans ATCC 10231 105 / ml Cryptococcus neoformans ATCC MYA-4564 105 / ml Pneumocystis jirovecii (carinii) ATCC PRA-159 105 / ml Adenovirus 21 - AV1645 BEI NR-56500 105 / ml Adenovirus Type 31 Culture Fluid (1 mL) ZeptoMetrix 0810073CF 104 / ml Adenovirus Type 40 Culture species F

[0752] Strain Dugan Fluid (1 mL) ZeptoMetrix 0810084CF 103 / ml Coxsackievirus A10 ATCC VR-168 105 / ml Coxsackievirus A21 ATCC VR-850 105 / ml Human Coxsackievirus B1, Conn-5 BEI NR-58650 105 / ml Cytomegalovirus (CMV) ZeptoMetrix 0810003CF 102 / ml Cytomegalovirus C9209 BEI ARP-2082

[0753] ABI Adv HFS / CMV C9209- Biotech 1 105 / ml Enterovirus 71 - Tainan / 4643 / 1998 BEI NR-471 105 / ml Epstein-Barr Virus (EBV) ZeptoMetrix 0810008CF 105 / ml Human Echovirus 30 Strain Bastianni ATCC VR-1660 105 / ml Herpes simplex Virus 1 (HSV1) ATCC AV-VR-1778 105 / ml Human herpes virus 1 (Herpes simplex

[0754] virus 1 strain H5) ATCC VR-260 105 / ml Human Herpes Virus 6 (HHV6) Type 6B ZeptoMetrix 0810072CF 105 / ml Herpes simplex virus Type 2 Culture fluid ZeptoMetrix 0810217CF 103 / ml Influenza A Virus - Influenza A Virus,

[0755] A / Puerto Rico / 8-MC / 1934 (H1N1) BEI NR-29022 106 / ml Influenza A virus - A / Hong Kong / H090-756- V1(0) / 2009 (H3N2) BEI NR-44344 105 / ml Influenza B virus - B / Taiwan / 2 / 1962 BEI NR-3181 104 / ml Influenza B Virus - B / Sydney / 507 / 2006

[0756] (Yamagata Lineage) BEI NR-36526 104 / ml Measles Virus -MVs / Maryland.USA / 18.18

[0757] [B3] BEI NR-52251 104 / ml Measles Virus ZeptoMetrix 0810025CF 104 / ml Human Metapneumovirus TN / 83-1211 BEI NR-22227 104 / ml

[0758]

[0759] P107173W001

[0760] 57

[0761] Mumps Virus ZeptoMetrix 0810079CF 105 / ml Human Parainfluenza Virus 1,

[0762] H PI V1 / FRA / 29221106 / 2009 BEI NR-48680 104 / ml Human Parainfluenza virus 2 - Greer BEI NR-3229 104 / ml Human Parainfluenza virus Type 4 - M-25 BEI NR-3237 102 / ml Human Parechovirus (HPeV) ZeptoMetrix 0810147CF 105 / ml Human Respiratory Syncytial Virus - A 1998 / 3-2 BEI NR-28529 105 / ml Human respiratory syncytial virus A2 ATCC VR-1540 102 / ml HCoV-229E EVAg 011N-03868 104 / ml HCOV-NI63 EVAg 011N-03868 104 / ml HCoV-0043 EVAg 011N-03868 104 / ml HCoV-SARS-CoV EVAg 011N-03868 104 / ml HCoV-MERS-CoV EVAg 011N-03868 104 / ml

[0763]

[0764] ATCC: American Type Culture Collection, 10801 University Blvd, Manassas, VA 20110, USA BEI: 10801 University Blvd, Manassas, VA20110 USA

[0765] EVAg: UVE-UMR190 Emerging Viral Diseases Medical Faculty, 27 Boulevard Jean Moulin - 13385 Marseille cedex 5 - France

[0766] AR Bank: Antimicrobial Resistance Isolate Bank (AR Isolate Bank), 1600 Clifton Road, Mail Stop: H17-3, Atlanta, GA 30329-4027 USA

[0767] ZeptoMetrix: 14957 Collection Center Drive, Chicago, IL, 60693-0149 USA

[0768] Example 4

[0769] Overall clinical performance

[0770] Evaluation Method

[0771] The clinical performance of the SCoV-2 / Influenza A I Influenza B / RSV mmultiplex test of the invention (SAMBA) has been evaluated in comparison with comparator assays TaqPath COVID-19 test (ThernoFisher) and TaqPath COVID-19, FluA / B, RSV Combo kit (ThermoFisher).

[0772] Specimens from symptomatic and asymptomatic individuals collected in sample buffers (Universal transport media (UTM), Copan UTM-RT, Sigma Virocult media and SAMBA Respiratory Specimen buffer) have been tested on the SAMBA SCoV-2 / Influenza A I Influenza B / RSV mmultiplex test.P107173W001

[0773] 58

[0774] Results

[0775] Specimens from 818 individuals, with 469 specimens collected in Universal transport media (UTM) and 349 specimens collected in SAMBA specimen buffer have been tested. Results are shown in Table 3 below.

[0776] 5 The overall sensitivity and specificity of SAMBA using TaqPath as a comparator test for each viral target is shown in Table 3 below.

[0777] The overall invalid rate (IC failure) was 1.59% (13 / 818), and the overall technical failure rate (instrument mechanical or software failure) was 0.98% (8 / 818).

[0778] Table 3: Clinical performance of the SAMBA SCoV-2 / Flu / RSV Test compared to

[0779] 0 TaqPath COVID-19 test and TaqPath COVID-19, FluA / B, RSV Combo kit

[0780] Sample No of PPA NPA Target + / + j - +

[0781] buffer specimens ±A z / _- (95% Cl) (95% Cl)

[0782] 1 97.95% 100.00% SARS-CoV-2 469 143 0 323 3 (94.11-100.00) (98.86-100.00)

[0783] 100% 100% Flu A 469 39 0 430 0

[0784] (90.97-100.00) (99.15-100.00) UTM

[0785] 100% 100% Flu B 469 13 0 456 0

[0786] (75.29-100.00) (99.19-100.00) 100% 100% RSV 469 57 0 412 0

[0787] (93.73-100.00) (99.11-100.00) 100.00% 100% SARS-CoV-2 349 100 0 249 0

[0788] (96.38-100.00) (98.53-100.00) 100% 100% Flu A SAMBA 349 29 0 320 0

[0789] (88.06-100.00) (98.85-100.00) Specimen

[0790] 100% 100% Flu B Buffer 349 8 0 341 0

[0791] (63.06-100.00) (98.92-100.00) 100% 100% RSV 349 16 0 333 0

[0792] (79.41-100.00) (98.90-100.00) 1 98.78% 100.00% SARS-CoV-2 818 243 0 572 3 (96.48-100.00) (99.36-100.00)

[0793] 100% 100% Flu A 818 68 0 750 0

[0794] All (94.72-100.00) (99.51-100.00) samples 100% 100% Flu B 818 21 0 797 0

[0795] (83.89-100.00) (99.54-100.00) 100% 100% RSV 818 73 0 745 0

[0796]

[0797] (95.07-100.00) (99.51-100.00)

[0798] + / + concordant positive, + / - SAMBA positive / comparator negative, - / - concordant negative, - / + SAMBA negative / comparator positive

[0799] 1Ct of samples negative by SAMBA were 34.69, 34.73 and 35.67 when tested on TaqPath 5 COVID-19 Combo kitP107173W001

[0800] 59

[0801] PPA (positive percentage agreement) and NPA (negative percentage agreement) are used to assess the agreement between a test and a reference standard. PPA is analogous to sensitivity, representing the proportion of true positives identified by the test, while NPA is analogous to specificity, representing the proportion of true negatives identified by the test.

[0802] Conclusions

[0803] The SCoV-2 / Influenza A / Influenza B / RSV multiplex test of the present invention provides high diagnostic accuracy and rapid turn-around time allowing clinicians to promptly and accurately diagnose the associated respiratory infections at the point-of-care, thus allowing quicker initiation of appropriate therapy and more effective clinical management.

[0804] Aspects of the invention are set forth in the following numbered paragraphs.

[0805] 1. A method for determining whether a sample includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:

[0806] i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAGGACAATCAGACAACTACTATTC (SEQ ID NO:1), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / or

[0807] ii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAATTGTGCGTGGATGAG (ORF8-SA-F1; SEQ ID NO:4); or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.P107173W001

[0808] 60

[0809] 2. A method according to paragraph 1, which comprises use of forward and reverse nucleic acid amplification primer pairing (i), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:1, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:2, or the complement thereof.

[0810] 3. A method according to paragraph 1 or 2, which comprises use of forward and reverse nucleic acid amplification primer pairing (ii), wherein the forward nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:4, or the complement thereof, and the reverse nucleic acid amplification primer comprises a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0811] 4. A method according to any of paragraphs 1 to 3, which comprises use of the forward and reverse nucleic acid amplification primer pairings (i) and (ii).

[0812] 5. A method according to any preceding paragraph, wherein the amplification reaction comprises a polymerase chain reaction (PCR) amplification reaction.

[0813] 6. A method according to paragraph 5, wherein the PCR amplification reaction is a realtime (rt) PCR.

[0814] 7. A method according to any preceding paragraph, which further comprises reverse transcribing SARS-CoV-2 RNA of the sample and amplifying a product of the reverse transcription by an amplification reaction using one or more of the forward and reverse nucleic acid amplification primer pairings.

[0815] 8. A method according to paragraph 7, which further comprises isolating nucleic acid of the sample before reverse transcribing SARS-CoV-2 RNA of the sample present in the isolated nucleic acid.

[0816] 9. A method according to any preceding paragraph, which further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to SARS-CoV-2 nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

[0817] 10. A method according to paragraph 9, wherein:

[0818] a product of the amplification reaction using primer pairing (i) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or a nucleic acid sequence that hasP107173W001

[0819] 61

[0820] at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof;

[0821] a product of the amplification reaction using primer pairing (ii) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0822] 11. A method according to paragraph 10, wherein the detector probe for primer pairing (i) comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or the complement thereof.

[0823] 12. A method according to paragraph 10 or 11, wherein the detector probe for primer pairing (ii) comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or the complement thereof.

[0824] 13. A method according to any of paragraphs 9 to 12, wherein the detector probe comprises a fluorescent label.

[0825] 14. A method according to paragraph 13, wherein the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0826] 15. A method according to any preceding paragraph, wherein the sample is a biological sample obtained from a subject suspected of being infected with SARS-CoV-2.

[0827] 16. A method according to any preceding paragraph, wherein the sample is a nasopharyngeal or a throat swab sample obtained from a subject suspected of being infected with SARS-CoV-2.

[0828] 17. A method according to any preceding paragraph which is an in vitro method.

[0829] 18. An oligonucleotide, which comprises:

[0830] a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or a nucleic acid sequence that has at least 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof;P107173W001

[0831] 62

[0832] a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4); or a nucleic acid sequence that has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof;

[0833] a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or a nucleic acid sequence that has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof; or

[0834] a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or a nucleic acid sequence that has at least 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof.

[0835] 19. An oligonucleotide according to paragraph 18, which comprises:

[0836] a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or the complement thereof;

[0837] a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4), or the complement thereof;

[0838] a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or the complement thereof; or

[0839] a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or the complement thereof.

[0840] 20. An oligonucleotide according to paragraph 18 or 19, which is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0841] 21. A pair of oligonucleotide primers for determining whether a sample includes SARS-CoV-2 nucleic acid, which comprises:

[0842] i) a first primer, which comprises a nucleic acid sequence of: GAGGACAATCAGACAACTACTATTC (SEQ ID NO:1), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or a nucleic acid sequence that has atP107173W001

[0843] 63

[0844] least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / or

[0845] ii) a first primer, which comprises a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4); or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

[0846] 22. A pair of oligonucleotide primers according to paragraph 21 , which comprises:

[0847] i) a first primer, which comprises a nucleic acid sequence of: GAGGACAATCAGACAACTACTATTC (SEQ ID NO:1), or the complement thereof; and a second primer, which comprises a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or the complement thereof; and / or

[0848] ii) a first primer, which comprises a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4), or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or the complement thereof.

[0849] 23. A pair of oligonucleotide primers according to paragraph 21 or 22, wherein each primer is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0850] 24. A set of oligonucleotides for amplifying SARS-CoV-2 nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:

[0851] a pair of oligonucleotide primers according to any of paragraphs 21 to 23; and

[0852] a detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

[0853] 25. A set of oligonucleotides according to paragraph 24, which comprises:P107173W001

[0854] 64

[0855] i) a pair of primers according to paragraph 21 (i) or 22(i); and a detector probe, which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / or

[0856] ii) a pair of primers according to paragraph 21 (ii) or 22(H); and a detector probe, which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

[0857] 26. A set of oligonucleotides according to paragraph 24 or 25, which comprises:

[0858] i) a pair of primers according to paragraph 21 (i) or 22(i); and a detector probe, which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or the complement thereof; and / or

[0859] ii) a pair of primers according to paragraph 21 (ii) or 22(H); and a detector probe, which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or the complement thereof.

[0860] 27. A set of oligonucleotides according to paragraph 26, which comprises:

[0861] i) a pair of primers according to paragraph 22(i); and a detector probe, which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or the complement thereof; and / or

[0862] ii) a pair of primers according to paragraph 22(H) ; and a detector probe, which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or the complement thereof.

[0863] 28. A set of oligonucleotides according to any of paragraphs 24 to 27, wherein the detector probe is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.

[0864] 29. A kit for determining whether a sample includes SARS-CoV-2 nucleic acid, which comprises a set of oligonucleotides according to any of paragraphs 24 to 28, wherein the pair of primers are for real-time PCR amplification of SARS-CoV-2 target nucleic acid, and wherein the detector probe comprises a fluorescent label.P107173W001

[0865] 65

[0866] 30. A kit according to paragraph 29, which comprises a first set of oligonucleotides according to paragraph 25(i), 26(i), or 27(i), and a second set of oligonucleotides according to paragraph 25(H), 26(H), or 27(H).

[0867] 31. A kit according to paragraph 29 or 30, which comprises a first set of oligonucleotides according to paragraph 27(i), and a second set of oligonucleotides according to paragraph 27(H).

[0868] 32. A kit according to any of paragraphs 29 to 31, wherein the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

[0869] 33. A kit according to any of paragraphs 29 to 32, which further comprises an RNA-dependent DNA polymerase for reverse transcription of SARS-CoV-2 RNA, and a DNA-dependent DNA polymerase for real-time PCR (rt-PCR) amplification and detection of reverse-transcribed SARS-CoV-2 RNA using the, or each, pair of primers and the detector probe.

[0870] 34. A kit according to any of paragraphs 29 to 33, which further comprises dNTPs and / or reaction buffer for reverse transcription and rt-PCR amplification.

[0871] 35. A kit according to any of paragraphs 29 to 34, which further comprises a swab stick for obtaining a nasopharyngeal or a throat swab sample from a subject.

[0872] 36. A kit according to any of paragraphs 29 to 35, which further comprises a lysis / binding buffer, an elution buffer, and Optionally, a wash buffer, for extracting nucleic acid from a biological sample obtained from a subject.

[0873] 37. Use of an oligonucleotide according to any of paragraphs 18 to 20, a pair of primers according to any of paragraphs 21 to 23, a set of oligonucleotides according to any of paragraphs 24 to 28, or a kit according to any of paragraphs 29 to 36, for determining whether a sample includes SARS-CoV-2 nucleic acid.

[0874] 38. Use according to paragraph 37 in a method according to any of paragraphs 1 to 17.

Claims

P107173W00166CLAIMS1. A method for determining whether a sample includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAGGACAATCAGACAACTACTATTC (SEQ ID NO:1), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: AGTCTGAACAACTGGTGTAAGT (SEQ ID NO:2), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / orii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of: GAATTGTGCGTGGATGAG (SEQ ID NO:4); or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of: TACAAGACTACCCAATTTAGGTTC (SEQ ID NO:5), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

2. A method according to claim 1, which further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to SARS-CoV-2 nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

3. A method according to claim 2, wherein:a product of the amplification reaction using primer pairing of claim 1(i) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: TGAGGTTCAACCTCAATTAGAGATGG (SEQ ID NO:3), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,P107173W0016796%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof;a product of the amplification reaction using primer pairing claim 1(ii) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of: CTGGTTCTAAATCACCCATTCAGT (SEQ ID NO:6), or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

4. A method for determining whether a sample includes Influenza A nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:7, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:7, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:8, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:8, or the complement thereof; and / orii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 10; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 10, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:11, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:11 , or the complement thereof.

5. A method according to claim 4, which further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to Influenza A nucleic acid sequence that is conserved in Influenza A, or the complement thereof.

6. A method according to claim 5, wherein:P107173W00168a product of the amplification reaction using primer pairing of claim 4(i) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO:9, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:9, or the complement thereof;a product of the amplification reaction using primer pairing of claim 4 (ii) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO:12, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 12, or the complement thereof.

7. A method for determining whether a sample includes Influenza B nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using one or more of the following forward and reverse nucleic acid amplification primer pairings:i) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 13, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 13, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 14, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:14, or the complement thereof; and / orii) a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:16; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 16, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 17, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:17, or the complement thereof.

8. A method according to claim 7, which further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to Influenza B nucleic acid sequence that is conserved in Influenza B, or the complement thereof.P107173W001699. A method according to claim 8, wherein:a product of the amplification reaction using primer pairing of claim 7(i) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO:15, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:15, or the complement thereof;a product of the amplification reaction using primer pairing of claim 7(ii) is detected by hybridising the product to a nucleic acid detector probe which comprises a nucleic acid sequence of SEQ ID NO: 18, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:18, or the complement thereof.

10. A method for determining whether a sample includes Respiratory syncytial virus (RSV) nucleic acid, which comprises amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an amplification reaction using the following forward and reverse nucleic acid amplification primer pairings:a forward nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 19, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 19, or the complement thereof; and a reverse nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NQ:20, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NQ:20, or the complement thereof.

11. A method according to claim 10, which further comprises detecting a product of the amplification reaction by hybridising the product to a nucleic acid detector probe, wherein the detector probe hybridises to RSV nucleic acid sequence that is conserved in RSV type A and RSV type B, or the complement thereof.

12. A method according to claim 11 , wherein:a product of the amplification reaction using primer pairing of claim 10 is detected by hybridising the product to one or more nucleic acid detector probes comprising a nucleic acid sequence selected from SEQ ID NO:21 and SEQ ID NO:22, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,P107173W0017096%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 21 and SEQ ID NO:22, or the complement thereof.

13. A method for determining whether a sample includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and / or Influenza A and / or Influenza B and / or Respiratory syncytial virus (RSV) nucleic acid, which comprises carrying out a method according to any one of claims 1 to 3 and / or claims 4 to 6 and / or claims 7 to 9 and / or claims 10 to 12, respectively.

14. A method according to any preceding claim, wherein the amplification reaction comprises a polymerase chain reaction (PCR) amplification reaction, optionally, wherein the PCR amplification reaction is a real-time (rt) PCR.

15. A method according to any preceding claim, which further comprises reverse transcribing SARS-CoV-2 RNA, and / or Influenza A RNA, and / or Influenza B RNA, and / or RSV RNA of the sample and amplifying a product of the reverse transcription by an amplification reaction using one or more of the forward and reverse nucleic acid amplification primer pairings of claims 1 , 4, 7, and 10.

16. A method according to any of preceding claim, wherein the detector probe comprises a fluorescent label.

17. A method according to claim 16, wherein the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label, optionally, wherein the detector probe is a hydrolysis probe, or a molecular beacon probe which includes nucleotide sequence which has complementarity to itself.

18. A method according to any preceding claim, wherein the sample is a biological sample obtained from a subject suspected of being infected with SARS-CoV-2, and / or Influenza A, and / or Influenza B, and / or RSV, optionally, wherein the sample is a nasopharyngeal or a throat swab sample.

19. A method according to any preceding claim, which further comprises isolating nucleic acid of the sample before reverse transcribing and amplifying the isolated nucleic acid.

20. An oligonucleotide, which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-22, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-22, or the complement thereof.P107173W0017121. A pair of oligonucleotide primers for determining whether a sample includes SARS-CoV-2 nucleic acid, which comprises:i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:1, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:2, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:2, or the complement thereof; and / orii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:4; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:4, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:5, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:5, or the complement thereof.

22. A set of oligonucleotides for amplifying SARS-CoV-2 nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:a pair of oligonucleotide primers according to claim 21 ; anda detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in SARS-CoV-2, or the complement thereof.

23. A set of oligonucleotides according to claim 22, which comprises:i) a pair of oligonucleotide primers according to claim 21 (i); and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:3, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:3, or the complement thereof; and / orii) a pair of oligonucleotide primers according to claim 21 (ii); and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:6, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, orP107173W0017299% identity along its entire length with a nucleic acid sequence of SEQ ID NO:6, or the complement thereof.

24. A pair of oligonucleotide primers for determining whether a sample includes Influenza A nucleic acid, which comprises:i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:7, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:7, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:8, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:8, or the complement thereof; and / orii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO: 10; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 10, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO:11, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:11, or the complement thereof.

25. A set of oligonucleotides for amplifying Influenza A nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:a pair of oligonucleotide primers according to claim 24; anda detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in Influenza A, or the complement thereof.

26. A set of oligonucleotides according to claim 25, which comprises:i) a pair of oligonucleotide primers according to claim 24(i); and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:9, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:9, or the complement thereof; and / orP107173W00173ii) a pair of oligonucleotide primers according to claim 24(H); and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:12, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:12, or the complement thereof.

27. A pair of oligonucleotide primers for determining whether a sample includes Influenza B nucleic acid, which comprises:i) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:13, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 13, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NO:14, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 14, or the complement thereof; and / orii) a first primer, which comprises a nucleic acid sequence of SEQ ID NO:16; or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 16, or the complement thereof; and a second nucleic acid amplification primer, which comprises a nucleic acid sequence of SEQ ID NO: 17, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 17, or the complement thereof.

28. A set of oligonucleotides for amplifying Influenza B nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:a pair of oligonucleotide primers according to claim 27; anda detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in Influenza B, or the complement thereof.

29. A set of oligonucleotides according to claim 28, which comprises:i) a pair of oligonucleotide primers according to claim 27(i); and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:15, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, orP107173W0017499% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 15, or the complement thereof; and / orii) a pair of oligonucleotide primers according to claim 27(H) ; and a detector probe, which comprises a nucleic acid sequence of SEQ ID NO:18, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 18, or the complement thereof.

30. A pair of oligonucleotide primers for determining whether a sample includes RSV nucleic acid, which comprises:a first primer, which comprises a nucleic acid sequence of SEQ ID NO: 19, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO: 19, or the complement thereof; and a second primer, which comprises a nucleic acid sequence of SEQ ID NQ:20, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NQ:20, or the complement thereof.

31. A set of oligonucleotides for amplifying RSV nucleic acid by an amplification reaction, and detecting a product of the amplification reaction, which comprises:a pair of oligonucleotide primers according to claim 30; anda detector probe, wherein the detector probe hybridises to nucleic acid sequence that is conserved in RSV, or the complement thereof.

32. A set of oligonucleotides according to claim 31 , which comprises:a pair of oligonucleotide primers according to claim 30; and one or more detector probes comprising a nucleic acid sequence selected from SEQ ID NO:21 and SEQ ID NO:22, or a nucleic acid sequence that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity along its entire length with a nucleic acid sequence of SEQ ID NO:21 and SEQ ID NO:22, or the complement thereof.

33. An oligonucleotide according to claim 20, a pair of oligonucleotide primers according to any one of claims 21 , 24, 27 and 30, or a set of oligonucleotides according to any one of claims 22, 23, 25, 26, 28, 29, 31 and 32, wherein each oligonucleotide is up to 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides long.P107173W0017534. A kit for determining presence or absence in a sample of one or more of SARS-CoV-2, Influenza A, Influenza B and RSV nucleic acid, which comprises a pair of oligonucleotide primers according to any one of claims 21, 24, 27 and 30, or a set of oligonucleotides according to any one of claims 22, 23, 25, 26, 28, 29, 31 and 32; optionally, wherein the pair of primers are for real-time PCR amplification of target nucleic acid; and wherein the detector probe comprises a fluorescent label, optionally, wherein the detector probe further comprises a quencher for quenching fluorescence of the fluorescent label.

35. A kit according to claims 34, which further comprises an RNA-dependent DNA polymerase for reverse transcription of SARS-CoV-2 RNA, Influenza A RNA, Influenza B RNA and RSV RNA and a DNA-dependent DNA polymerase for real-time PCR (rt-PCR) amplification and detection of reverse-transcribed SARS-CoV-2 RNA, Influenza A RNA, Influenza B RNA and RSV RNA using the, or each, pair of oligonucleotide primers and the detector probe, or a set of oligonucleotides.

36. A kit according to claims 34 or 35, which further comprises dNTPs and / or reaction buffer for reverse transcription and rt-PCR amplification.

37. A kit according to any one of claims 34 to 36, which further comprises a swab stick for obtaining a nasopharyngeal or a throat swab sample from a subject.

38. A kit according to any of claims 34 to 37, which further comprises a lysis / binding buffer, an elution buffer, and optionally, a wash buffer, for extracting nucleic acid from a biological sample obtained from a subject.

39. Use of an oligonucleotide according to claim 20, a pair of oligonucleotide primers according to any one of claims 21, 24, 27 and 30, or a set of oligonucleotides according to any one of claims 22, 23, 25, 26, 28, 29, 31 and 32, or a kit according to any of claims 34 to 38, for determining whether a sample includes one or more of SARS-CoV-2 nucleic acid, Influenza A nucleic acid, Influenza B nucleic acid and RSV nucleic acid, respectively.

40. Use according to claim 39 in a method according to any one of claims 1 to 19.